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THESIS ABSTRACT 
 
_________________________________________ 
 
Sickle cell disease (SCD) is one of the most common severe monogenic 
disorders. Pulmonary hypertension (PHT) is a serious complication of SCD. 
The gold standard diagnosis for PHT is direct measurement of pulmonary 
artery pressure and resistance using cardiac catheterisation (RHC) but this is 
invasive. Transthoracic echocardiography (TTE) is non-invasive and is 
universally used to screen for PHT, with tricuspid regurgitation velocity 
maximum (TR Vmax) used as a surrogate for right ventricular systolic 
pressure (RVSP). Currently, there remains debate regarding the accuracy and 
reliability of TR Vmax in the identification of pulmonary hypertension (PHT), 
particularly since TR Vmax is not always measureable.  
 
This thesis combines a retrospective analysis of echocardiographic data and 
additional information regarding patient demographics, clinical parameters 
and laboratory results. The thesis examines the reliability of measuring TR 
Vmax and other echo-derived parameters of pulmonary hypertension. The 
association between TR Vmax and the echo-derived parameters of pulmonary 
hypertension, as well as the benefit of these markers when TR Vmax is not 
measureable, was evaluated using multiple univariate, bivariate, and 
regression analyses of clinical and echocardiography data. Furthermore, it 
investigates the ability of echo-derived markers of pulmonary hypertension to 
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predict end-points as defined by death, PHT on RHC and sickle cell crisis 
requiring hospital admission.  
 
The thesis concludes that TR Vmax is measurable in under half of TTE 
studies and that other echo parameters are more frequently measureable. 
There is no significant agreement between TR Vmax and echo-derived 
markers of pulmonary hypertension. No TTE measure, or combination of 
measures, reliably predicted end-points. However pulmonary artery 
acceleration time (PA AccT) was the best single predictor with 6-fold greater 
influence in the prediction of end-points.  
 
These findings suggest that screening for PHT should include PA AccT, which 
is attainable in most patients and may provide a better predictor of end-points 
within this disease cohort. Additionally, enforcing a more robust definition of 
possible PHT by combining TR Vmax with a higher threshold of >2.6m/s and 
PA AccT <105ms with symptoms and other clinical findings may prove 
advantageous for individuals with sickle cell disease.  
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CHAPTER 1  
 
_________________________________________ 
INTRODUCTION AND RESEARCH QUESTION 
 
  1.1  Subject Overview  
 
Sickle cell disease (SCD) is one of the most common severe monogenic 
disorders affecting an estimated 30 million persons worldwide and 12 000 
within the United Kingdom alone.1,2 It is an autosomal recessive disease 
defined by a haemoglobin mutation resulting in abnormal haemoglobin 
function and break down. This irregularity commonly leads to anaemia, 
inflammation, microvasculature obstruction and potential ischaemic 
reperfusion injury to vital organs.3-5 Related to this vasculopathy are an 
increasing number of reported incidents of sudden death of unknown cause.3 
Advances in treatment and management have led to improvements in life 
expectancy.6 However a consequence of this aging population, is the 
recurrent presentation of chronic irreversible organ damage within the third 
decade of life.4,7  
 
A frequent and serious complication of SCD is pulmonary hypertension (PHT). 
It has been identified in approximately one third of patients with SCD and 
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reported in approximately 75% of SCD patients at autopsy.8-10 Pulmonary 
vasculopathy and the development of PHT is thought to be driven primarily by 
chronic haemolytic anaemia but this is further compounded by other 
independent factors including surgical splenectomy, thromboembolism, lung 
fibrosis and hypoxemia, increases in growth factor, renal insufficiencies and 
genetic factors.5 The gold standard method for the diagnosis of PHT involves 
direct measurement of pulmonary artery pressure and resistance using 
cardiac catheterisation. However this technique is invasive and cannot be 
routinely performed. As such, there is a reliance on non-invasive assessments 
such as echocardiography.  
 
Transthoracic echocardiography (TTE), a non-invasive mainstay methodology 
for the assessment of PHT, uses tricuspid regurgitation velocity maximum (TR 
Vmax) as a surrogate for right ventricular systolic pressure (RVSP).11-14 Other 
echocardiography parameters including pulmonary artery acceleration time 
(PA AccT), and tricuspid annular plane systolic excursion (TAPSE) or right 
ventricular tissue Doppler imaging systolic wave velocity (RV TDI S’) may also 
be used. Despite the use of echocardiography as a diagnostic and monitoring 
tool, the accuracy of this non-invasive measurement remains uncertain and 
there is debate regarding the reliability of using this approach in the 
management and monitoring of patients with SCD, particularly when it may 
not be measurable in all patients.15-17 To date, the best practice in identifying, 
determining prevalence, and monitoring of PHT has not been clearly 
established and further research into the usefulness of non-invasive 
echocardiographic parameters is necessary.13  
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  1.2 Research Question and Objectives 
 
The aim of this study was to investigate the use of transthoracic 
echocardiography (TTE) in the diagnosis and risk-stratification of pulmonary 
hypertension (PHT) in patients with sickle cell disease (SCD).  
 
The objectives were to:  
 
1) Assess how often the four commonly used markers of potential PHT (tricuspid 
regurgitation velocity maximum (TR Vmax), pulmonary artery acceleration 
time (PA AccT), tricuspid annular plane systolic excursion (TAPSE) and right 
ventricular tissue Doppler imaging systolic wave (RV TDI S’)) were 
measureable; and assess how often TR Vmax, PA AccT, TAPSE and RV TDI 
S’ were classified as normal, intermediate or possible PHT risk.  
 
2) Test agreement between echo-derived parameters of pulmonary hypertension 
(TR Vmax, PA AccT, TAPSE and RV TDI S’); and determine, when TR Vmax 
is not measurable, how often other echo indices indicate PHT. 
 
3) Determine if TR Vmax, PA AccT, TAPSE and RV TDI S’ are associated with 
end-points as defined by death, pulmonary hypertension (PHT) on right heart 
catheterisation (RHC) and sickle cell crisis requiring hospital admission; and 
test whether a redefinition of pulmonary hypertension based on a combination 
of echo markers prove a better predictor of pulmonary hypertension than 
using TR Vmax alone.   
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  1.3  Thesis Overview 
 
This thesis is in the style of a traditional thesis by monograph. It is structured 
into seven chapters, divided into sections and sub-sections. 
 
Chapter 2 introduces the topics of sickle cell disease (SCD), pulmonary 
hypertension (PHT) and transthoracic echocardiography (TTE). It then 
comprises a literature review focusing on the relationship between 
transthoracic echocardiography and PHT in SCD. This literature review 
provides the background information necessary for the development of the 
methodological component of the thesis which is designed to meet the 
research objectives. 
 
Chapter 3 outlines the study design and study patients including the inclusion 
and exclusion criteria applied. The technical aspects required for 
measurement of echocardiographic parameters are comprehensively 
described. The collection and collation methods for demographic, clinical and 
biochemistry data are also outlined. A general overview of the methods and 
statistical analysis is summarised in this section. Specific details relating to 
the individual research objectives are outlined in chapters 4, 5 and 6.  
 
Chapter 4 examines objective 1 focussing on the ability to measure the four 
commonly used markers of PHT. The frequency of measurement of the echo 
parameters relative to the classification of risk (Option A) is also assessed. 
Echo parameters are also considered in relation to demographic, laboratory 
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and clinical data. This chapter draws conclusions based on reliability and 
accuracy in the measurement of echo parameters within this patient cohort. 
 
Chapter 5 addresses objective 2. Testing agreement between echo-derived 
parameters of pulmonary hypertension is of particular importance given the 
findings relating to the measurability of echo parameters (Chapter 4). Further 
analysis is then performed to focus on the diagnostic benefit of the remaining 
echo parameters when TR Vmax is not measureable.  
 
Chapter 6 draws comparisons between echo parameters and end-points 
(death, PHT on RHC and sickle cell crisis requiring hospital admission) in 
order to examine their influence in the prediction of end-points. This chapter 
addressed research objective 3. The relationship between end-points and 
echo parameters when TR Vmax  is not measurable is also assessed. Further 
to this, the chapter investigates whether a redefinition of pulmonary 
hypertension based on a combination of echo markers is a better predictor of 
pulmonary hypertension than using TR Vmax alone.    
 
Chapter 7 provides a final overall discussion regarding the findings of the 
research project. I also compare and contrast the findings of the study with 
the current literature. The significance and limitations of the research project 
are outlined and final conclusions regarding the research are drawn. Possible 
clinical applications and suggestions for future research are also proposed.  
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  1.4  Research Schema  
 
The research schema provides an overview of the research project  (figure 1). 
The schema defines four distinct research stages of which this thesis forms 
stage four. Prof Kerrie Mengersen and Dr Fiona Harden at the Queensland 
University of Technology (QUT), Queensland, Australia, have overseen all 
components of the research project. Prof John Chambers has been an 
external onsite associate supervisor on behalf of QUT and Guy’s and St 
Thomas’ Foundation Trust, London, United Kingdom.  
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Figure 1. Research schema outlining stages of the research project.	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CHAPTER 2 
 
_________________________________________ 
BACKGROUND AND LITERATURE REVIEW 
 
  2.1 Sickle cell disease (SCD) 
 
 2.1.1 Overview of SCD 
 
Sickle cell disease (SCD) is a genetic disorder characterised by abnormal red 
blood cells. It is one of the most common haemogobinopathies worldwide and 
is now recognised as a major public health concern.18   SCD is an autosomal 
recessive disease meaning that two copies of an abnormal gene must be 
present in order for the disease to develop. Individuals with one mutated gene 
and one normal gene are sickle carriers. These individuals remain largely 
asymptomatic and are generally regarded as having a benign condition.19 
 
Sickle cell disease (SCD) results from abnormalities at the level of β-globin in 
the haemoglobin molecule (figure 2.1a and 2.1b). These abnormalities lead to 
the synthesis of S haemoglobin (HbS), a structural variable that is far less 
soluble than normal haemoglobin.20 When deoxygenated, this single point 
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mutation leads to alterations in the polymerisation process causing distortion 
and clumping of the haemoglobin molecule.  
         
 
Figure 2.1a. The crystal structure of human deoxy-haemoglobin. Figure 2.1b. A crystal model of two Hb S 
hemoglobin molecules clumping together (as cited in Harrington (1997): The high resolution crystal structure of 
deoxyhaemoglobin S).21 
2.1a 
2.1b 
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There are a variety of subtypes of SCD with the homozygous variant Hb SS, 
the most common and severe form of the disease. Individual genetic 
mutations and interactions of the haemoglobin molecule lead to other SCD 
subtypes such as Haemoglobin C (HBC), characterised by abnormalities at 
the 6th position of the β–globin chain.22 HBC is typically a milder form of the 
disease with patients experiencing fewer symptoms. Another disease 
subtype, β–thalassemia, develops as a result of disruption in β–globin gene 
production.22 The severity of the β–thalassemia subtype presents along a 
spectrum with β0 thalassemia thought to be more severe with a poorer 
prognosis compared to β+ thalassemia.23  
 
 2.1.2 Pathophysiology of SCD 
 
Alterations in the polymerisation process cause haemoglobin molecules to 
accumulate into long fibres ultimately reducing flexibility and distorting cell 
form.24 As a consequence, the erythrocytes become ‘sickled’ shape and are 
typically rigid and more dense (figure 2.2).24 In addition, sickle cells have 
exposed receptors that bind to integrins on the endothelial surface, making 
them ‘sticky’.25 This results in reduced membrane fluidity and blockages that 
alter blood flow properties through diminutive capillaries (figure 2.3a and 
figure 2.3b). A secondary consequence of this is oxygen deficiency to highly 
vascularised tissues and vital organs.5 Sickled red blood cells are unusually 
friable and prone to destruction so they only survive in the circulation for about 
one tenth of the time that normal erythrocytes might remain in the blood 
supply.26 Therefore individuals with SCD have a lower median haemoglobin 
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concentration level; approximately 9 g/dL. 27 This is compared with a mean of 
13.8-15.7 g/dL for the normal adult population. 28 
 
 
Figure 2.2. Pathology sample demonstrating polychromatophilic RBCs (reticulocytes) (small single arrow), target cell 
(large single arrow) and sickle cell (double arrow) (as cited in Lazarchick (2009): Sickle cell disease – RBC 
morphology).29  
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Figure 2.3a shows normal red blood cells flowing freely in a blood vessel and a cross-section of a normal red blood 
cell with normal hemoglobin (inset). Figure 2.3b shows abnormal, sickled cells blocking blood flow in a blood vessel 
and a cross-section of a sickle cell with abnormal (sickle) hemoglobin forming abnormal stiff rods (inset) (as cited in 
National Heart, Lung and Blood Institute (NHLBI) (2015): What is Sickle Cell Disease?) 30 
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Polymerisation of haemoglobin S cells causes severe obstruction to 
microvasculature. Haemolysis leads to chronic anaemia. The resultant 
deprivation of oxygen supply to tissues and the circulatory system causes 
ischaemic reperfusion injury.31,32 This leads to the amplification of 
inflammatory and oxidative stress, activation of the innate immune response, 
and drives infarction of highly vascularised multiple critical organs; spleen, 
kidneys, liver, lung, brain, muscle and bone.31,32, 3-5 
 
 2.1.3 Clinical manifestations of SCD 
 
Infarction of bone marrow is the most common and characteristic complication 
of SCD. In the UK, this results in an average of two hospital admissions or 
emergency room visits per patient per year.33 Bone infarction is associated 
with severe pain at the site of ischaemia and is commonly referred to as an 
‘acute painful crisis’. Acute chest syndrome is the next most common, causing 
severe chest pain and desaturation.34 Combined, acute painful crises and 
acute chest syndromes are responsible for over three-quarters of the deaths 
of clinically stable individuals with sickle cell disease.33 Aside from these, 
sickle cell deaths for ‘healthy’ individuals can also be attributed to stroke, 
more specifically acute haemorrhages.33 Caution is thus required when 
labelling individuals as ‘healthy’ as sickle cell disease can be clinically silent 
with insidious accumulating vascular damage leading to sudden and 
unexplained fatality.35 Current literature suggests an increasing number of 
reported incidents of sudden death of unknown cause.3  
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In chronically unwell patients, organ failure secondary to renal failure, 
congestive heart failure, pulmonary complications or chronic debilitating 
cerebrovascular events, is the most common cause of death with some 
related to other underlying disease processes such as lupus and renal 
tuberculosis.33,36 It is well recognised that sickle cell disease accelerates 
organ destruction, considerably decreasing life expectancy. Other major 
complications of SCD include sepsis, renal failure, seizures, and pregnancy 
related complications.33,37  
 
There are a number of cardiac manifestations associated with SCD. Low level 
haemoglobin is associated with hyperdynamic hearts (high ejection fractions, 
increased total stroke volume and cardiac output), heart murmurs, and 
cardiac enlargement.38,39 SCD patients also suffer characteristic widespread 
vascular occlusions that can affect virtually any organ, including the heart. 
Myocardial ischemia, biventricular dysfunction, and pulmonary hypertension 
are recognised cardiac manifestations of SCD.38,40-42  
 
Common symptoms experienced by individuals with sickle cell disease 
include fatigue, breathlessness, joint pain, delayed growth, jaundice, rapid 
heart rate, and increased susceptibility to infections.30  
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  2.1.4 Incidence and Prevalence of SCD 
 
SCD is the most prevalent autosomal blood disease worldwide with 
approximately 250 000 affected children born every year.38 It has been 
estimated that 72 000 Americans have SCD and, while the exact United 
Kingdom (UK) figures are not definitively known, a national enquiry into 
patient outcomes and deaths estimated 12 000 affected individuals.2,5 The 
first annual report from the national haemoglobinopathy registry (NHR), 
released in late 2014, showed 7 300 SCD registrations but the NHR 
emphasises this is not reflective of a complete list of individuals with SCD.43 
According to these figures, in the UK London has the largest cohort of SCD 
patients with an estimated 4 500 patients registered.43  
 
SCD most commonly affects those with ancestors from Africa, South or 
Central American and the Caribbean Islands. Less commonly, it affects 
Mediterranean, Indian, and Saudi Arabian populations. Currently African and 
Caribbean populations make up over three quarters of the total UK SCD 
cohort and immigration from these countries means that the incidence of SCD 
in the United Kingdom continues to rise.43 
 
In 2005, England introduced complete neonatal screening for 
haemoglobinopathy leading to a substantive improvement in mortality among 
pediatric patients. Initially regarded as ‘a disease of childhood’, SCD had a 
high mortality rate with relatively few patients reaching adult life. In 1972 
Diggs estimated a mean survival age of 14 years with over half of deaths 
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occurring before the 5th year of life.44 However with the advent of neonatal 
screening and appropriate prophylaxis, survival to age 20 years has increased 
from 79% for patients born before 1975 to 89% for children born in or after 
1975.45  
 
Current life expectancy for adults with SCD has vastly improved and is now 
38-50 years. Alongside screening and infection precautions, this improvement 
in life expectancy is likely the result of better management standards and 
significant advances in treatment.6 However with an aging sickle cell 
population, chronic organ dysfunction and cardiovascular complications are 
increasingly evident, with pulmonary hypertension and left ventricular 
dysfunction commonly presenting within the third decade of life.4,7,14  
 
 
 2.2 Pulmonary hypertension (PHT) 
 
Pulmonary hypertension (PHT) is present when the mean pulmonary artery 
pressure exceeds 25 mmHg at rest or 30 mmHg with exercise.46 It is one of 
the major vasculopathic complications of SCD, and has been identified in 6-
32% of patients with SCD and up to 75% of patients at autopsy.8-10 PHT 
therefore emerges as a leading cause of mortality and morbidity within this 
cohort.14,41,47,48 Moreover this raises the possibility of PHT serving as a clinical 
phenotype for SCD related sudden death. 
 
Chronic hemolytic anemia has been proposed as a primary driver of 
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pulmonary vasculopathy but this is further compounded by other independent 
factors including: impaired nitric oxide bioavailability; chronic hypoxemia and 
lung fibrosis; thromboembolism; chronic liver disease; surgical splenectomy; 
thromboembolism and asplenia; increased growth factor and genetic 
predisposition.5,8  
 
PHT results from reduced blood flow in the pulmonary arteries.  While there 
are a variety of potential underlying pathologies, broadly the pathogenesis is 
as follows: Reduced nitric oxide bioavailability results in haemolysis and 
oxidative stress, trigging chronic pulmonary vasoconstriction.49 This leads to 
an injury response mechanism with consequent collagen deposition and 
vascular smooth muscle proliferation (figure 2.4). Over time, vascular smooth 
muscle hyperplasia creates a relatively fixed lesion, compounded in later 
stages by irregular, adhesion molecules.50 Thrombosis results in further 
occlusion of the vessel lumen resulting in accelerated progression of 
pulmonary hypertension.49 On histopathological analysis, PHT is 
characterised by the proliferation of medial smooth-muscle cells and 
endothelial cells in the small pulmonary arteries.51  
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Figure 2.4. Progression of pulmonary hypertension in sickle cell disease and thalassemia (as cited in Kato (2007): 
Pulmonary hypertension in sickle cell disease: relevance to children; minor alterations by author).49  
No PHT 
Mild PHT 
Moderate PHT 
Severe PHT 
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The gold standard method for the diagnosis of PHT involves direct 
measurement of pulmonary artery pressure and resistance using right heart 
cardiac catheterisation (RHC). Assessment of PHT has been criticised with 
studies concluding the addition of cardiac catheterisation for the estimation of 
PHT does not improve patient management or outcome.52,53 In addition, 
cardiac catheterisation is invasive and cannot be routinely performed on all 
individuals. Therefore, there is a reliance on non-invasive assessments such 
as transthoracic echocardiography. 
 
 
  2.3  Pulmonary hypertension (PHT) and   
   Echocardiography 
Transthoracic echocardiography (TTE) is a widely utilised, non-invasive 
diagnostic tool that can be used in the identification of potential PHT. It is 
comparatively inexpensive, and has no known side effects. Most commonly 
tricuspid regurgitation velocity maximum (TR Vmax) is used as a surrogate for 
PHT through the estimation of right ventricular systolic pressure (RVSP) 
(Figure 2.5).11-14 Other echo-derived parameters including pulmonary artery 
acceleration time (PA AccT), tricuspid annular plane systolic excursion 
(TAPSE) and right ventricular tissue Doppler imaging systolic wave (RV TDI 
S’) are also suggestive of PHT.57,58.  
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 2.3.1 Tricuspid Regurgitation Velocity Maximum (TR Vmax)  
Tricuspid regurgitation velocity maximum (TR Vmax) is measured on the 
modal part of a continuous wave signal following parallel alignment between 
echocardiography cursor and tricuspid regurgitation jet (figure 2.5). High TR 
Vmax has been associated with adverse events and mortality but there is 
uncertainty about the feasibility of this technique and the cutoffs that are 
indicative of an abnormality.14,47,54 Tricuspid regurgitation signals are often 
more easily measured in severe disease secondary to concomitant RV 
dilatation but this may not be true in all patients. Moreover, some patients with 
significant PHT will have TR Vmax that cannot be measured due to minimal 
TR volume. Current literature suggests TR Vmax is recordable in as little as 
39% of the population. Further to this, not all patients with detectable TR will 
have velocity profiles suitable for measurement.55,56 Accurate estimation of TR 
Vmax is imperative as under or over estimation may limit early disease 
diagnosis or alter clinical management resulting in suboptimal care for 
patients.  
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Figure 2.5. Continuous Wave Doppler of a tricuspid valve regurgitation jet with peak tricuspid regurgitation 
velocity maximum (TR Vmax) measured (author’s own image).  
  
 2.3.2 Pulmonary Artery Acceleration Time (PA AccT) 
 
Unlike TR Vmax, pulmonary artery acceleration time (PA AccT) is measurable 
in most individuals and does not rely on unattainable Doppler traces. PA AccT 
can be estimated by measuring the period of time between the onset of 
forward pulmonary flow to the onset of peak pulmonary flow velocity and has 
been reported to be a useful parameter in the identification of PHT (figure 
2.6).59 PA AccT has been significantly correlated with TR Vmax. Shorter PA 
AccT also suggests higher pulmonary vascular resistance (PVR) but these 
assumptions are based on relatively little data.60-62  
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Figure 2.6. Pulsed wave Doppler of the right ventricular outflow tract (RVOT) demonstrating a measure of the 
pulmonary artery acceleration time (PA AccT) (author’s own image). 
 
 
 2.3.3  Tricuspid annular plane systolic excursion (TAPSE) 
 
TAPSE is a measure of right ventricular longitudinal excursion during 
myocardial contraction. It is well recognised that, with increases in right heart 
pressures, there is eventual and progressive dilatation of the right ventricle 
ultimately leading to RV systolic dysfunction and failure. TAPSE, whilst not an 
estimate of right ventricular systolic pressure (RVSP), can be used to 
determine right ventricular myocardial performance through the evaluation of 
RV longitudinal function using M-Mode at the tricuspid annulus (figure 
2.7).57,63 It is especially appealing in clinical practice given the ease and 
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frequency with which it can be measured.64 Good correlation between 
TAPSE, overall RV ejection fraction (EF) and prognostic value has also been 
demonstrated in patients with pulmonary hypertension.57,65 However despite 
this support, there remain concerns regarding inter-operator variability and the 
obvious limitations of a one-dimensional approach in systolic function 
assessment of a three-dimensional right ventricle.57  
 
 
Figure 2.7. M-Mode trace with a measurement of tricuspid annular plane systolic excursion (TAPSE) (author’s own 
image).  
 
 
 2.3.4  Right Ventricular Tissue Doppler Imaging Systolic Wave  
  (RV TDI S’) 
 
Tissue Doppler imaging (TDI) is an extension of conventional Doppler flow 
echocardiography and can be used to asses global and regional left 
ventricular systolic function.66 Similarly, right ventricular tissue Doppler (TDI) 
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provides valuable information relating to RV systolic function in the 
longitudinal plane. Peak systolic velocities (S’) measured in the basal 
segment of the free RV wall have proven to be reliable indices in diagnosis 
and evaluation of prognosis for patients with RV dysfunction (figure 2.8).  
Currently, there is limited data on the usefulness of RV TDI S’ in the 
identification of PHT.  
 
 
Figure 2.8. Tissue Doppler imaging (TDI) of the basal segment of the right ventricular free wall with a measurement 
demonstrating the systolic (S’) wave velocity (RV TDI S’) (author’s own image). 
 
 
Despite the widespread use of echocardiography as a diagnostic tool, the 
measurability and accuracy of non-invasive measurements remains uncertain 
and there is debate regarding the reliability of using this approach in the 
management and monitoring of patients with sickle cell disease.15-17 Currently, 
the best practice in identifying, determining prevalence, and monitoring of 
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PHT has not been clearly established and further research into the usefulness 
of non-invasive echocardiographic parameters is necessary.13 
 
 
  2.4  Literature review 
 
Invasive and non-invasive estimates of PHT report occurrence of between 6-
32% in individuals with SCD8,12,14,67  
 
In a US study of 195 patients, 63 (32%) SCD patients had PHT as defined by 
a TR Vmax of >2.5ms. The same study reported an associated increased risk 
of death of 36% for the PHT group when compared to 13% for the 132 
patients without PHT.14 It has since been suggested that although an 
impressive association between increased pulmonary pressures and mortality 
was reported, the degree of PHT was modest making a causal relationship 
questionable and a simple correlate relationship a reasonable assumption.3 
 
Similarly a tertiary centre screening study of 80 subjects reported 32 (40%) 
SCD patients with PHT as defined by TR Vmax >2.5ms.67 The study reported 
an interpretable TR velocity in all 80 patients. Given that TR Vmax cannot be 
reliability measured in all individuals, this raises questions regarding the 
accuracy and reliability of Doppler measurements performed within this 
study.58  
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By contrast, in a recent large-scale French study of 398 patients, Parent and 
colleagues reported that only 24 (6%) patients with SCD had PHT confirmed 
on RHC; the recommended gold standard. Echo alone was shown to have a 
low positive predictive value for PHT (25%).13 This was supported by a 
smaller scale US based study (25 patients) which also reported improved 
specificity (81%) when utilising a TR Vmax of higher than 2.88m/s as a 
screening tool for PHT.68 The French study also proposed the potential 
benefit of a redefinition of the current values of >2.5ms.13 In this study a TR 
velocity of 2.9m/s, 3.0m/s or greater was found to have a greater predictive 
value for RHC confirmed PHT.13 This is also supported by Desai and 
colleagues who found a larger proportion of patients had PHT on RHC when 
categorised using a TR Vmax >2.9m/s as opposed to >2.5m/s.12,69 
 
Most recently, a UK based retrospective study involving 170 SCD adults 
demonstrated elevated TR in 48 (29%) patients.70 This study was able to 
identify a correlation between raised TR Vmax and mortality using continuous 
univariate analysis, highlighting a greater than 4-fold risk of death for those 
patients with a TR velocity greater than 2.5m/s. Importantly, however, when 
investigated using multivariate analysis, this study did not find TR Vmax as an 
independent risk factor for death.70 
 
Although some studies suggest that TR Vmax obtained by echocardiography 
may over-estimate the prevalence of PHT, elevated TR Vmax remains a 
recognised independent predictor of mortality in SCD.13,14,47,54,67 In a recent 
study of 310 subjects, non-invasive TR Vmax (as a surrogate for the 
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classification of PHT) and invasive measurements of PHT obtained using 
RHC were achieved with 86% accuracy.71 However the use of un-blinded 
operators, the retrospective nature of the study and the high degree of 
statistical variance may have biased the results of this study.  
 
The relationships between PHT and other echo parameters have also been 
examined. Pulmonary artery acceleration time (PA AccT) has been shown to 
significantly correlate with TR Vmax.61 A shorter PA AccT was suggestive of 
higher pulmonary vascular resistance (PVR), with some studies proposing 
that a cut off value of 90ms is sufficient to accurately identify patients with 
pulmonary hypertension.60 Likewise, for a PA AccT shorter than 100 ms, 
sensitivity of identification of PHT was estimated at 78% with specificity of 
100%.60 Additional studies have shown normal PA AccT (>120-130ms) 
eliminates PHT with almost 100% sensitivity.64 Yared and colleagues studied 
371 patients and found PA AccT could be used to estimate peak systolic 
pulmonary artery pressure independent of TR Vmax, thereby increasing the 
percentage of patients in whom transthoracic echocardiography could be 
used to quantify pulmonary artery systolic pressure.61 Similarly, it has been 
suggested that combining a PA AccT shorter than 93 ms with other echo 
indices would make this variable even more discriminative72. Although there 
remains debate regarding the accuracy and reliability of using this echo 
parameter to identify PHT, the majority of evidence suggests PA AccT may 
have an important role in identification of PHT and should be further 
investigated.  
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Several equations have also been derived for the calculation of mean 
pulmonary artery pressure (MPAP) based on PA AccT.  One early seminal 
study suggested the regression equation: MPAP = 73 – 0.42 x PA AccT. 60 
However this formula based technique was founded on a small sample size 
with a limited amount of semi-quantitative data. The heavy influence of 
ventricular function, heart rate, stroke volume and cardiac output also raised 
questions regarding the validity of using this technique. 60 
 
TAPSE and RV TDI S’ are reliable predictors of RV systolic function.57 A 
Taiwanese study of 625 patients demonstrated reasonable correlation 
between both TAPSE and RV TDI S’ with RV systolic function in the setting of 
mild to moderate TR. This study used a modified Simpson’s method from two 
orthogonal echocardiographic planes.73 By contrast, when TR was severe, 
there was poor correlation between TAPSE and RV TDI S’ and RV systolic 
function using the same technique. This finding was supported by a smaller 
scale study (23 patients) which suggested under the conditions of volume or 
pressure overload, there was poor correlation between TAPSE and RV 
dilatation and dysfunction.74 In children, a study of 30 infants with PHT 
reported TAPSE as superior to RV TDI S’ in the identification of PHT and a 
retrospective study of 86 infants with PHT demonstrated diminished TAPSE 
as an indicator of progression to death.75,76 However, this study also 
suggested that RV global performance was a better indicator of death 
compared to RV free wall performance (i.e. TAPSE). The majority of studies 
still maintain support for the use of TAPSE and RV TDI S’ in the assessment 
of PHT. It has been reported that RV TDI S’ <12cm/s predicts PASP > 
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40mmHg with a sensitivity of 85% and a specificity of 93.3%.66 Similarly S’ 
values taken from both tricuspid annuli have been shown to be significantly 
lower in patients with PHT when compared with controls.77 The evidence 
suggests promise for using both TAPSE and RV TDI S’ in the prediction of 
SCD related PHT.  
 
Wider research studies involving 76 patients has shown right ventricular 
diameter (RVD) significantly increases in patients with pulmonary 
hypertension (as defined by a peak of >35mmHg or a mean >25mmHg).58 
This study also suggested a benefit in combining morphological parameters 
(i.e. right ventricular diameter) with physiological parameters (i.e. the time 
from the beginning of isovolumic contraction to the systolic peak on TDI) for 
predicting the presence of pulmonary hypertension. 
 
Dahiya et al (2010) investigated the usefulness of calculating pulmonary 
vascular resistance (PVR) using TR Vmax and RVOT velocity time integral in 
a cohort of 72 patients and 42 control patients.78 In this study, echo derived 
PVR was positively correlated (r=0.77) with PVR measured using invasive 
methods. They further described a high sensitivity between groups (93%) in 
patients with elevated PVR in cardiac catheterisation and a good sensitivity 
(91%) between groups for patients with normal PVR in cardiac 
catheterisation. It was felt however that PVR by non-invasive methods 
underestimated PVR when this was markedly elevated.78  
 
A number of studies have reported hazard ratios linking elevated pulmonary 
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artery systolic pressure as assessed on echocardiography with 
death.3,14,47,70,79 However these studies were all conducted among adult 
populations in Western countries with some of the earliest publications 
reporting a very high hazard ratio based on a small number of events.80 
 
A recent review by the American Society of Echocardiography concluded that 
based on the evidence, a multiple parameter approach was the most useful in 
the investigation of pulmonary hypertension. It was suggested that further 
investigation and refinement in right heart hemodynamics combined with 
invasive measures of the right heart was needed.81  
 
A review of the current literature identifies a lack of research consistency and 
very little scrutiny into the diagnostic potential of other echo parameters of 
PHT and the benefit of using a combination of echo parameters in the 
prediction of PHT in the SCD population. Further research is required to 
provide evidence of clinical advantage in the identification and medical 
management of subgroups with a high-predicted mortality due to sickle cell 
related pulmonary hypertension.  
  
________________________________________________________________________________________ 
Echocardiographic measures of pulmonary hypertension and the prediction of end-points in sickle cell disease 	  
58 
CHAPTER 3 
 
_________________________________________ 
METHODOLOGY AND RESEARCH DESIGN 
 
 
 The methodology section provides an overview of the general methods 
applied in Chapters 4, 5, and 6. A more detailed and specific description of 
methodology can be found in the individual chapters. 
    
 
    3.1 Study Design 
 
This retrospective study was performed at a single tertiary institute. It involved 
collaboration between Cardiology and Haematology at Guy’s and St Thomas’ 
Foundation Trust, United Kingdom and the Science and Engineering Faculty 
at the Queensland University of Technology (QUT), Australia. Data included 
demographics, clinical parameters and echocardiographic results collected 
between November 2007 and October 2014. An expert investigator performed 
all echocardiographic measurements using stored digital loops obtained 
during TTE. The remaining data was collected using medical records and 
patient information previously documented as part of routine clinical practice. 
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These data included a combination of clinical parameters, physical 
assessment, laboratory results and medical consultation (refer to appendix A1 
for a comprehensive list of parameters). 	  
    
 
   3.2 Study Patients 
 
The population comprised 625 patients who were referred for routine annual 
echocardiograms with further studies indicated on clinical grounds. Patient 
selection was based on referrals received through a specialist SCD clinic. 
Patients were included and excluded based on the criteria below (table 3.1).	  
 
Table 3.1. Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
1. Sickle Cell Diagnosis 
(Haemoglobin SS, SC, 
Sβ° or Sβ+ thalassemia)  
2. 17 years and older; 
male and female  
3. TTE assessment 
between 2007-2014c  
Echo Data Clinical Data 
1. TTE not performeda 
2. Non diagnostic TTEb 
1. TTE not performeda 
2. Non diagnostic TTE 
3. Acute sickle cell crisis 
requiring hospital 
admission within four 
weeks preceding TTEd 
 
 
aPatients who did not attend (DNA) for echocardiography assessment. bOnly TTEs with adequate or better image 
quality were included. c With referral to Guy’s and St Thomas’ Trust based on annual review, investigation of elevated 
PAP or the monitoring of elevated PAP; PAP = pulmonary artery pressures. dIn line with current recommendations. 82 
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3.3 Echocardiography Data  
 
3.3.1 Equipment and information technology 
 
Comprehensive TTE assessment was performed using commercially 
available ultrasound systems: GE Vivid 7, Vivid I or Vivid E, and/or Philips 
IE33 or Cx50. A 3MHz, or 5MHz fixed array transducer was used. 
Echocardiography images were recorded and stored in digital format for 
further off line, frame-by-frame analysis. All TTE images were then reviewed 
using GE EchoPac workstations with measurements performed by a single 
expert investigator holding both Australian and British Echocardiography 
qualifications (Grad Dip in Cardiac Ultrasound, British Society of 
Echocardiography TTE accreditation) (KV). This investigator was blinded to 
clinical parameters prior to review. 
 
 3.3.2  Image acquisition 
 
TTE image acquisition was performed by a cardiac physiologist or cardiology 
doctor trained in echocardiography. Transthoracic echocardiography images 
were performed as per Guy’s and St Thomas’ Foundation Trust sickle cell 
minimum standards (appendix A2) and in line with recommendations by the 
American Society of Echocardiography (ASE) (endorsed by the European 
Association of Echocardiography (EAE)).57 Two-dimensional B-mode, M-
mode, colour, spectral and tissue Doppler modalities were used. Both 
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qualitative and quantitative assessments were performed. Patients were 
scanned in the left decubitus position using three anatomical acoustic 
windows (parasternal, apical and subcostal) where possible. Based on 2-3 
cardiac cycle loops, measurements were made to reflect the average 
representative cardiac cycle.  
 
 3.3.3  Measurements and technique 
 
All eligible scans were reviewed to determine echocardiographic parameters 
considered relevant to PHT. Measurements included estimation of tricuspid 
regurgitation velocity maximum (TR Vmax), pulmonary artery acceleration 
time (PA AccT), tricuspid annular plane systolic excursion (TAPSE), right 
ventricular tissue Doppler imaging systolic wave (RV VTI S’), end-diastolic 
pulmonary regurgitation velocity (EDPR), right ventricular velocity time integral 
(RV VTI), mean pulmonary pressure (MPAP), left atrial (LA) and right atrial 
(RA) areas, right ventricular (RV) size, left ventricular outflow tract (LVOT) 
diameter, left ventricular outflow tract velocity time integral (LVOT VTI), and 
inferior vena cava (IVC) collapsibility. Additional calculations were performed 
in order to estimate pulmonary vascular resistance (PVR), stroke volume (SV) 
and cardiac output (CO) (refer to list of equations). 
 
Tricuspid regurgitation velocity maximum (TR Vmax) was measured on the 
modal part of the continuous wave signal using the optimal signal from all 
views (PS short and long, 4-chamber (ch)).  Spectral envelopes with well-
defined, dense spectral profile were measured in keeping with current 
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recommendations and guidelines. The pulmonary artery acceleration time (PA 
AccT) was measured by pulsed Doppler of the right ventricular outflow tract 
(RVOT) just proximal to the insertion of the pulmonary valve leaflets. 
Acceleration time (AccT) was measured from the onset of flow to the onset of 
peak pulmonary flow velocity. The tricuspid annular plane systolic excursion 
(TAPSE) was measured from nadir to the systolic peak of the M-mode trace 
at the lateral tricuspid valve annulus in a 4-ch view. The right ventricular tissue 
Doppler imaging systolic wave (RV VTI S’) was obtained from the RV free wall 
in the apical 4-ch view. Pulsed wave Doppler sample volume was placed at 
the tricuspid annulus with the modal signal of the peak systolic wave 
measured. For further information regarding baseline measurements and 
measurement technique please refer to appendix A3.  
 
 3.3.4  Echocardiography parameters by category 
 
Echo parameters were used to classify groups according to disease severity 
(classification of risk Option A). These groups were normal, intermediate and 
possible PHT. Cut-points were based on evidence and recommendations 
from the literature. 12,13,57,69,82-84 Further details regarding risk classification will 
be provided in Chapter 4 (page 69-70).  
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   3.4  Demographic and Clinical Data 
 
Demographic information including sex, age and genotype was collected 
using patient records. Additional clinical history details including number of 
hospital admissions, reason for hospital admissions, blood transfusion history, 
and associated medical history were recorded using patient records and 
clinical letters. Pulse rate (HR), systolic and diastolic blood pressure (BP), and 
pulse oximetry (O2 saturations) were acquired from clinic letters. Significant 
confounding causes of pulmonary hypertension including LV dysfunction, 
coronary artery disease, valve disease, asthma, smoker, obesity, and COPD 
were also noted where available. Current and previous drug therapies 
including Hydroxycarbamide were recorded.  All patient data were obtained 
within a 3-6 month window of the patient’s TTE examination.  
 
 
   3.5  Biochemistry Data 
 
Results of full blood count tests, assessments of urea and electrolytes (U and 
E), and liver function tests (LFTs) were obtained and recorded. Markers of 
haemolysis (such as lactate dehydrogenase (LDH) and reticulocyte count) 
were noted. All biochemistry data collection was obtained using Electronic 
Patient Record (EPR), a GSTT internal online IT medical record system. 
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  3.6 Additional testing 
 
Details regarding pulmonary capillary wedge pressure and pulmonary 
vascular resistance were obtained from right heart cardiac catheterisation 
(RHC) as reported on Tomcat (GSTT Cardiology reporting IT system).  An 
invasive mean pulmonary artery pressure of >25mmHg was considered 
consistent with pulmonary hypertension. 
 
 
  3.7 Data Management 
 
All information was obtained from internal digital medical records. Permission 
to access electronic medical records was granted by Guy’s and St Thomas’ 
Foundation Trust. Multiple onsite electronic hospital IT systems were used 
including: Echopac, Medcon, EPR, and Tomcat. All electronic systems were 
accessible from the Cardiac Outpatients departments both at Guy’s, and St 
Thomas’ hospitals.  
 
All patient information was recorded in password protected Excel 
spreadsheets in digital electronic form (appendix A4). These were stored on 
secure networked hospital IT systems. Patients were given unique 
identification numbers and any personal identifiers were removed. A data 
management planning checklist was completed as part of this process and 
updated throughout the duration of the project (appendix A5). 
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  3.8 End-points 
 
In order to perform clinical comparisons with echocardiography, demographic 
and laboratory data, end-points were required. End-points were defined as: 1) 
death; 2) mean pulmonary artery pressure >25mmHg on right heart 
catheterisation (RHC); 3) sickle cell crisis requiring hospital admission. End-
points will be discussed in further detail in Chapter 6 (page 120).  
 
 
  3.9 Statistical Analysis 
 
Statistical analysis was performed using IBM SPSS Statistics software 
(version 21) and R designed by R Development Core Team. Descriptive and 
frequency summaries (counts and percentages) were performed on all 
variables. A p-value of 0.05 was used to infer statistical significance. P-values 
<0.000 are as reported in statistical analysis and indicate p<0.0005.85-88 A 
thorough description of individual statistical analyses necessary to meet the 
outlined objectives can be found within the independent chapters.85-88
 
  
 
  3.10  Research Ethics Statement  
 
Ethical approval was granted by the Queensland University of Technology 
(QUT) Human Research Ethics Committee, Australia (approval number 130 
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0000756; see appendix A6 for approval certificate). This research project was 
exempt from ethical approval through Guy’s and St Thomas’ Foundation 
Trust, United Kingdom (approval number 3906; see appendix A7 for letter of 
confirmation).  
 
Given this was a retrospective study and patients were de-identified, patients’ 
informed consent was not required. All measurements were obtained as part 
of routine clinical practice. There were no health and safety implications 
arising from this research.  
 
 
3.11  Resource and Funding  
 
There was no external funding or resource provided for completion of this 
project. This project formed collaboration between Guy’s and St Thomas’ 
Foundation Trust (GSTT) Cardiology and Haematology departments, and 
Queensland University of Technology (QUT). The principal investigator was 
awarded a Grant in Aid in order to assist with costs associated with the 
presentation of results, both nationally and internationally.  
   
 
  3.12 Individual Contribution to the Research Team 
 
The entirety of this research was the responsibility of the principal 
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investigator. This study was not dependent upon the work of a research team 
and was not part of an externally funded or sponsored project. Professor 
Kerrie Mengersen was the principal supervisor with Doctor Fiona Harden and 
Professor John Chambers associate supervisors. Professor Chambers was 
based at the research site, Guy’s and St Thomas’ Foundation Trust and both 
external organisation and supervisor memorandum of understanding (MOU) 
agreements were completed as part of this process (appendix A8 and A9). 
The principal investigator completed a QUT code of conduct for research 
certificate in line with QUT policy (appendix A10). 
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CHAPTER 4  
 
_________________________________________ 
TRICUSPID REGURGITATION VELOCITY 
MAXIMUM (TR VMAX) AND OTHER 
ECHOCARDIOGRAPHIC MEASURES OF 
PULMONARY HYPERTENSION: How 
measurable are they and what do they tell us? 
 
  4.1  Introduction 
 
Transthoracic echocardiography (TTE) is the non-invasive method of choice 
for the assessment of pulmonary hypertension (PHT). It uses tricuspid 
regurgitation velocity maximum (TR Vmax) as a surrogate for right ventricular 
systolic pressure.11-14 However, there remains debate regarding the 
appropriate cut point. In addition to this, TR Vmax is not always measurable. 
Other echo-derived parameters including pulmonary artery acceleration time 
(PA AccT), tricuspid annular plane systolic excursion (TAPSE) and right 
ventricular tissue Doppler imaging systolic wave (RV TDI S’) can also be used 
as markers of PHT. Despite the use of echocardiography as a diagnostic and 
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monitoring tool the feasibility, reliability and accuracy of using non-invasive 
measurements remains unclear.  
 
 
  4.2  Objective 1 
 
The aim of this chapter was to assess how often TR Vmax and other echo 
derived markers of pulmonary hypertension (PA AccT, TAPSE and RV TDI S’) 
were measurable and how often each echo parameter was classified as 
normal, intermediate or possible PHT risk (see section 4.3). The influence of 
other external continuous and categorical variables (clinical, demographic, 
laboratory data) relative to echo-derived markers of pulmonary hypertension 
was also examined.  
 
 
  4.3 Methods 
 
As described in chapter 3, echo parameters were used to classify groups 
according to disease severity. These groups were normal, intermediate and 
possible PHT and form classification of risk Option A. The previously 
suggested cut-point for PHT of TR Vmax ≥2.5m/s is now known to be 
nonspecific.13 Based on the evidence and recommendations from the 
literature, intermediate and possible PHT cut-points were defined as ≥2.6m/s 
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and >2.9 m/s, respectively. Table 4.1 outlines the ranges used for each of the 
categories. 12,13,57,69,82-84 
 
Table 4.1. Classification of risk table outlining categories of pulmonary hypertension (PHT) including defined 
ranges for echo parameters (normal, intermediate and possible PHT) (Option A). 
 
 
Abbreviations: TR Vmax = tricuspid regurgitation velocity maximum; PA AccT = pulmonary artery acceleration time; 
TAPSE = tricuspid annular plane systolic excursion; RV TDI S’ = right ventricular tissue Doppler imaging systolic 
wave. 
 
 
  4.4  Statistical Analysis 
 
For the assessment of echo parameters, distributions were assessed using 
means and standard deviations for parametric data, and medians and 
interquartile ranges (IQR) for non parametric data. TR Vmax was therefore 
defined by a median and IQR. For the remaining echo parameters, (PA AccT, 
TAPSE, RV TDI S’) means and standard deviations were used. Continuous 
variables were categorised into groups as per the classification of risk Option 
A (table 4.1) and counts and percentages were recorded for all categorical 
variables.  
 
Category Classification TR Vmax 
(m/s) 
PA AccT 
(ms) 
TAPSE 
(cm) 
RV TDI 
(m/s) 
1 Normal < 2.6 >105 > 1.8 > 0.12 
2 Intermediate 2.6 – 2.9 80-105 1.6-1.8 0.10-0.12 
3 Possible PHT > 2.9 < 80 < 1.6 < 0.10 
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For categorical data, a difference in mean was determined using Mann 
Whitney U Test for non parametric distributions or T-Test for parametric 
distributions. Linear regression was used to determine the influence of other 
external continuous and categorical variables on echo-derived markers of 
pulmonary hypertension (see individual and combined analysis under each 
subsection). Additional comparison variables included age, sex, disease type, 
haemoglobin, oxygen saturations (O2), pulmonary vascular resistance, stroke 
volume, cardiac output, and RV size. Further additional variables were 
collected (appendix A). However these were not considered relevant to the 
objective of this chapter and were therefore not included in further analysis. 
 
 
  4.5  Results 
 
 4.5.1 General 
A total of 625 sickle cell patients were referred for echocardiography 
assessment. Of the 625, 121 patients were excluded in accordance with the 
inclusion and exclusion criteria. There were 106 patients who did not attend 
(DNA) for echocardiography assessment (17%). In addition, there were 15 
patients who were excluded due to non-diagnostic echo images (2%) (figure 
4.1).  
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Figure 4.1. Selection criteria pathway for patients. Abbreviations: SCD = sickle cell disease; pts = patients; DNA = did 
not attend; TTE = transthoracic echocardiogram. 
 
Of the 504 patients, 323 (64%) were female and 181 (36%) were male. The 
median age was 34 years, ranging from 17 to 81 years of age.  (IQR: 26-45). 
Sickle cell disease (HbSS) (61%) and sickle cell anaemia (HbSC) (25%) were 
the most common disease types. Table 4.2 provides further details regarding 
demographics. 
 
 
 
 
125  
end-points  
504  
SCD pts 
reviewed 
625  
SCD pts referrals 
379 
 without  
end-points 
15  
pts with non-
diagnostic TTE 
106  
pts DNA 
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Table 4.2 Summary of patient demographics. *median (IQR) 
            
 
The mean Haemoglobin was 9.2 g/dL with a minimum of 4.0 g/dL and 
maximum of 15.4 g/dL (SD: 1.9) (figure 4.2).  
 
Variable( Number( Value(
Age( 504$ 34$(19)*$$
Sex( 504$
$$$$$Female$(%)$ 323$(64%)$$
Disease(Type( 504$
$$$$$HbSS$ 307$(61%)$
$$$$$HbSc$ 128$(25%)$
$$$$$$HbS/Betao$Thalassaemia$ 5$(1%$
$$$$$HbS/Beta+$Thalassaemia$ 6$(1%)$
$$$$HbS/HbE$ 21$(4%)$
$$$$$Other$ 37$(7%)$
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Figure 4.2. Histogram of the frequency of Haemoglobin (Hb) when assessed as a continuous variable. 
 
 
From the cohort of 504 sickle cell patients, there were 1002 
echocardiographic studies. Patients had between one and seven 
echocardiographic assessments performed between 9th November 2007 and 
31st October 2014.  
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 4.5.2 Tricuspid Regurgitation Velocity Maximum (TR Vmax) 
 
  4.5.2.1 General  
 
TR Vmax was measurable in 443 (44%) out of 1002 TTE assessments. The 
median TR Vmax was 2.3m/s with a minimum measureable velocity of 1.6m/s 
and a maximum measurable velocity of 4.3m/s (IQR: 2.1-2.6) (figure 4.3).  
 
 
Figure 4.3. Bar chart of the frequency of tricuspid regurgitation velocity maximum (TR Vmax) when assessed as a 
continuous variable. 
 
 
Relative to the classification of risk (option A), there were 332 (75%) TTE with 
a TR Vmax <2.6m/s, 83 (19%) with a TR Vmax consistent with intermediate 
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(between 2.6-2.9m/s) and 28 (6%) assessments with a TR Vmax consistent 
with possible PHT (>2.9m/s) (figure 4.4).  
 
 
Figure 4.4. Bar chart of the frequency of tricuspid regurgitation velocity maximum (TR Vmax) across categories of 
normal, intermediate and possible PHT (Option A). 
 
 
Based on the sample of 504 patients, the median TR Vmax for males was 
2.3m/s (IQR: 2.1-2.7) compared to 2.2m/s (IQR: 2.1-2.5) for females. There 
was no statistically significant difference in TR Vmax between males and 
females (Mann Whitney U test, p=0.07).  
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  4.5.2.2 Individual analysis 
 
Associations between TR Vmax and measured variables were examined. Age 
was found to be a significant predictor of TR Vmax (t441=0.000, p<0.000), 
with TR Vmax increasing by 0.05m/s for each 10-year increase in age, 
explaining 3.3% of the observed variation in TR Vmax.  This variation (3.3%) 
is very small. The implication of this poor model fit is further examined in the 
discussion (section 4.6). 
 
O2 sats were found to be a significant predictor of TR Vmax (t376=0.000, 
p<0.000), with TR Vmax decreasing by 0.03m/s for each percentage of O2 
Sats. O2 sats were able to explain 4.9% of the observed variation in TR Vmax. 
Again only a very small variation was noted. 
 
Similarly haemoglobin (Hb) was found to be a significant predictor of TR 
Vmax (t437=0.000, p<0.000), with TR Vmax decreasing by 0.04m/s for each 
g/dL of Hb. Hb was able to explain 4.4% of the observed variation in TR 
Vmax. Heart rate (HR) was also found to be a significant predictor of TR 
Vmax (t436=0.000, p<0.000), explaining 4.3% of the observed variation in TR 
Vmax. 
 
Left ventricular outflow tract velocity time integral (LVOT VTI), stroke volume 
(SV) and cardiac output (CO) were all significant predictors of TR Vmax 
(p<0.005) (see table 4.3).  
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  4.5.2.3 Combined analysis 
 
When age, O2 sats, Hb, LVOT VTI, SV, and CO were combined, the linear 
regression analysis was not significant. However, when repeated using only 
LVOT VTI, SV and CO combined an observed variation in TR Vmax of 6.4% 
was explained (variables summarised in table 4.3). Furthermore when 
repeated using a combination of Hb and HR, the model was able to predict 
7.9% of the variation in TR Vmax (t430=0.000, p<0.000). 
 
Table 4.3 Variables affecting tricuspid regurgitation velocity maximum (TR Vmax) and their statistical outcomes.  
Variable t P-value Variance (%) 
Age 441 < 0.000 3.3 
O2 sats 376 < 0.000 4.9 
Hb 437 < 0.000 4.4 
HR 436 < 0.000 4.3 
LVOT VTI 426 0.043 1 
SV 426 0.049 0.9 
CO 420 < 0.000 4.4 
LVOT VTI, SV, CO 421 < 0.005 6.4 
Hb and HR 430 < 0.000 7.9 
  
Abbreviations: O2 sats: oxygen saturations; Hb: haemoglobin; HR: heart rate; LVOT VTI: left ventricular outflow tract 
velocity time integral; SV: stroke volume; CO: cardiac output.  
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 4.5.3 Pulmonary Artery Acceleration Time (PA AccT)  
 
  4.5.3.1 General  
 
PA AccT was measurable in 626 (62%) of 1002 TTE assessments. The mean 
PA AccT was 118ms (SD: 23.5) (figure 4.5).  
 
 
Figure 4.5. Histogram of the frequency of pulmonary artery acceleration time (PA AccT) when assessed as a 
continuous variable. 
 
According to categorical analysis, there were 447 (71%) TTE with a PA AccT 
>105ms, 154 (25%) with a PA AccT between 80-105ms, and 25 (4%) with a 
PA AccT <80ms (figure 4.6).  
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Figure 4.6. Bar chart of the frequency of pulmonary artery acceleration time (PA AccT) across categories of normal, 
intermediate and possible PHT (Option A). 
 
There was no significant difference in mean PA AccT for males when 
compared to females (t435, p=0.336). The mean PA AccT for males was 
118ms (SD: 21.3) compared to 116ms (SD: 24.6) for females. 
 
  4.5.3.2 Individual analysis 
 
Age was found to be a significant predictor of PA AccT (t340=0.000, p<0.000), 
with PA AccT decreasing by 4ms for each 10-year increase in age, explaining 
4.4% of the observed variation in PA AccT. The variation (4.4%) is very small. 
The implication of this poor model fit is further examined in the discussion 
(section 4.6). 
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Heart rate (HR), was found to be a significant predictor of PA AccT 
(t609=0.000, p<0.000), with PA AccT decreasing by 5ms with each 10-beat 
increase in HR. It was able to explain 8.0% of the observed variation in PA 
AccT. O2 sats and haemoglobin (Hb) were not significant predictors of PA 
AccT (p>0.05).  Interestingly, cardiac output was also found not to be a 
significant predictor of PA AccT. Variables summarised in table 4.4.  
 
Table 4.4 Variables affecting pulmonary artery acceleration time (PA AccT) and their statistical outcomes. 
Variable t P-value Variance (%) 
Age 340  < 0.000 4.4 
Heart rate 690 < 0.000 8.0 
Cardiac Output 598 0.867 - 
 
   
  4.5.3.3 Combined analysis  
 
No combination of variables was significant in the prediction of PA AccT using 
linear regression. 
  
 4.5.4 Tricuspid Annulus Plane Systolic Excursion (TAPSE)   
 
  4.5.4.1 General  
TAPSE was measurable in 916 (91%) of 1002 TTE. The mean TAPSE was 
2.4cm (SD: 0.45) (figure 4.7).  
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Figure 4.7. Histogram of the frequency of tricuspid annular plane systolic excursion  (TAPSE) when assessed as a 
continuous variable. 
 
 
According to the classification of risk, there were 833 (91%) TTE with a 
TAPSE >1.8cm, 70 (8%) with a TAPSE between 1.6-1.8cm, and only 13 (1%) 
with a TAPSE <1.6cm (figure 4.8).  
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Figure 4.8. Bar chart of the frequency of tricuspid annular plane systolic excursion (TAPSE) across categories of 
normal, intermediate and possible pulmonary hypertension (Option A). 
 
 
Based on the sample of 504 patients there was no significant difference in 
mean TAPSE between males and females (t458, p=0.31). The mean TAPSE 
for males was 2.41cm (SD: 0.49) compared to 2.46cm (SD: 0.44) for females. 
Similarly HR had no significant impact on TAPSE (t896, p=0.483). 
 
  4.5.4.2 Individual analysis 
 
RV size (basal short axis dimension) was found to be a significant predictor of 
TAPSE (t905=0.000, p<0.000), with TAPSE increasing by 0.09cm for each 
centimeter increase in RV size, explaining 2.8% of the observed variation in 
TAPSE.   
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As expected RV TDI S’ was significantly associated with TAPSE explaining 
25% of the observed variation (t537=0.000, p<0.000). The variation (25%) is 
statistically and clinically relevant and will be further examined in the 
discussion (section 4.6) (variables summarised in table 4.5). Haemoglobin, 
Bilirubin and PVR were not significant predictors of TAPSE. 
 
Table 4.5. Variables affecting tricuspid annular plane systolic excursion (TAPSE) and their statistical outcomes.  
Variable t P-value Variance (%) 
RV size 905 < 0.000 2.8 
RV TDI S’ 537 < 0.000 25.0 
 
Abbreviations: RV: right ventricle; TDI S’: tissue Doppler imaging systolic wave.  
 
  4.5.4.3 Combined analysis 
 
When analysed using linear regression, a combination of variables including 
RV TDI S’, RV size, age and O2 sats was able to explain 32% of the observed 
variation.  
 
 4.5.5 Right Ventricular Tissue Doppler Imaging Systolic wave  
  (RV TDI S’) 
 
  4.5.5.1 General 
 
RV TDI S’ was measurable in 593 (59%) of 1002 TTE assessments. The 
mean RV TDI S’ was 0.14m/s (SD: 0.45) (figure 4.9).  
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Figure 4.9. Histogram of the frequency of right ventricular tissue Doppler imaging systolic wave (RV TDI S’) when 
assessed as a continuous variable. 
 
 
In terms of categorical analysis, there were 446 (75%) TTE with a RV TDI S’ 
>0.12m/s, 137 (23%) with a RV TDI S’ between 0.10-0.12m/s, and only 10 
(2%) with a RV TDI S’ <0.10m/s (figure 4.10).  
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Figure 4.10. Bar chart of the frequency of right ventricular tissue Doppler imaging systolic wave (RV TDI S’) across 
categories of normal, intermediate and possible pulmonary hypertension (Option A). 
 
 
There was no significant difference in mean RV TDI S’ for males when 
compared to females (t0.15, p=0.846). The mean RV TDI S’ for males was 
0.1438m/s (SD: 0.027) compared to 0.1432m/s (SD: 0.026) for females. 
 
  4.5.5.2 Individual analysis 
 
In contrast to TAPSE, RV size was not a significant predictor of RV TDI S’ 
(p>0.05). As outlined above, TAPSE was significantly associated with RV TDI 
S’ explaining 25% of the observed variation (t537=0.000, p<0.000).  
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  4.5.5.3 Combined analysis 
 
When combined, TAPSE, age and O2 sats were able to explain 28% of the 
observed variation in RV TDI S’.  
 
 4.5.6 Summary of Frequency and Percentage findings  
 
Table 4.6 provides a summary of frequencies and percentages of echo 
parameters compared to tricuspid regurgitation velocity maximum for both the 
intermediate and possible pulmonary hypertension groups.  
 
Table 4.6. Summary of the frequencies and percentages of echo parameters compared to tricuspid regurgitation 
velocity maximum (TR Vmax) for the intermediate and possible pulmonary hypertension groups.  
 
Abbreviations: TR Vmax = tricuspid valve regurgitation velocity; PA AccT = pulmonary artery acceleration time; 
TAPSE = tricuspid annular plane systolic excursion; RV TDI S’ = right ventricular tissue Doppler imaging systolic 
wave. 
 TR Vmax <2.6m/s TR Vmax 2.6-2.9m/s TR Vmax >2.9m/s 
 Intermediate Possible 
PHT 
Intermediate Possible 
PHT 
Intermediate Possible 
PHT 
PA 
AccT 
(n=626) 
42 
(7%) 
6 
(1%) 
16 
(3%) 
3  
(0.5%) 
6 
(1%) 
5 
(0.8%) 
TAPSE 
(n=916) 
24 
(3%) 
5 
(0.5%) 
10 
(1%) 
2 
(0.02%) 
3 
(0.03%) 
1 
(0.01%) 
RV TDI 
S’ 
(n=593) 
50 
(68%) 
1 
(0.2%) 
10 
(1.6%) 
2 
(0.3%) 
4 
(0.06%) 
2 
(0.3%) 
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  4.6  Discussion  
 
The results of this retrospective study of adults with sickle cell disease show 
that TR Vmax can be reliably measured in only 44% of patients. Previously, it 
has been suggested that TR Vmax was measurable in up to 86% of 
transthoracic echocardiography investigations.89 This previous study was 
based on patients with a mean age of 45 years, older in comparison to the 
mean age of the patients in the current study of 34 years. Older populations 
are more likely to have valvular heart disease that may lead to more 
measureable Doppler traces.90 A prospective study reported TR Vmax traces 
were of adequate quality in only 39% of patients with progressive systemic 
sclerosis referred for cardiac abnormality screening. Interestingly, an even 
lower detection rate was achieved in the control group (28%) when based on 
an age and sex matched population.91 These findings are consistent with 
those of the current study. 
 
Clinically, this means that more than half of the echo examinations performed 
would be of no benefit in the diagnosis of PHT if based on TR Vmax alone. 
Patients with non diagnostic images were excluded from the current study. It 
is therefore most likely insufficient TR volume was the main reason for an 
absence of a TR Vmax. The use of agitated saline contrast has been reported 
to assist in improving the TR Vmax envelope but in practice contrast requiring 
intravenous cannulation, may be impractical, particularly for this sizeable, 
largely asymptomatic patient cohort.55,57 Perhaps, on a case by case basis, 
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where the assessment of pulmonary haemodynamics is likely to change 
medical management for the patient, the use of agitated saline contrast to 
improve the TR Vmax envelope could be considered. 
 
PA AccT was found to be almost 20% more measurable than TR Vmax with 
62% of TTEs having a RVOT VTI trace recorded. In practice, a measurable 
PA AccT should be even more achievable with most, if not all, TTEs having 
an obtainable PA AccT. It is likely the reduced frequency is a reflection of a 
departmental change in protocol where the measurement of PA AccT was 
initially not required as part of a routine PHT assessment TTE examination. 
By comparison, a more recent study published in 2011 suggested that 
measurement of PA AccT was possible in 99.6% of TTEs performed.55,61  
 
In the current study, TAPSE was the most measurable echo parameter (91%). 
Although simple and easy to obtain, a limitation of this approach is the 
assumption that single segments of myocardium are representative of a 
complex three-dimensional structure. Moreover TAPSE acts as a surrogate 
for RV function and thus does not necessarily correlate with RVSP. Similar to 
PA AccT, RV TDI S’ also demonstrated a lower than expected frequency of 
measurability. This is most likely a reflection of the measure not always being 
performed rather than an inability to make the measurement. It may also be in 
part related to advancements in technology. This study was based on the 
collection of data since 2007. At this time TDI of the RV free wall was not 
routinely performed as part of an assessment for PHT in our tertiary centre.  
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TR Vmax was found to be suggestive of possible PHT in 6% of examinations 
(TR Vmax >2.9m/s). Parent and colleagues also found an incidence of 6% 
PHT as diagnosed on RHC amongst patients with SCD13. Similarly, the 
current study showed 25% of TTE assessments were consistent with 
intermediate or possible PHT (>2.6m/s). This is consistent with the 25-30% 
frequency shown by Parent et al and Zimbarra Cabrita et al.13,70 Higher 
frequencies, 32-40%, have been reported in some US studies using a TR 
Vmax cut off >2.5 m/s.14,67,68 This was expected given the cut point used in 
the current study was higher (>2.6m/s as compared to >2.5m/s). The 
discrepancy in findings between studies may also be due in part to differences 
in the clinical characteristics of the study populations.  
 
PA AccT was able to identify a higher number of TTE (29%) in the 
intermediate and possible PHT groups, when compared to TR Vmax (25%). 
This suggests that PA AccT may potentially identify a higher number of those 
at risk of PHT particularly when TR Vmax may not be measurable. However it 
needs to be considered that PA AccT was not corrected for heart rate (HR). 
Current recommendations suggest that a corrected PA AccT may assist in 
eliminating the influence of heart rate and that this is best performed at heart 
rates higher than 100bpm. The decision to leave heart rate uncorrected was 
made due to a very a small number (approximately 7%) of TTEs being 
performed when the HR was greater than 100bpm.  
 
Additional statistical comparisons demonstrated that a combination of LVOT 
VTI, stroke volume and cardiac output explained variations in TR Vmax. 
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Given that LVOT VTI alone contributed only 1% to variation, the true predictor 
was likely heart rate (used to calculate cardiac output) which may too have 
been influenced by Haemoglobin. As such, this comparison was repeated 
using Hb and HR combined which showed that these two variables were able 
to predict 7.9% of the variation in TR Vmax. It is most likely this is related to 
increases in TR Vmax that are associated with a compensatory high output 
state. This may be a result of anemia, pulmonary venous hypertension, and 
pulmonary vasculopathy incurred as a consequence of SCD. This finding is 
supported by Caughey et al.92 However it needs to be considered that the 
observed variation was small (7.9%) and even though it was significant, it still 
does not explain a large portion of the variation. This suggests that the 
statistical model may not be clinically relevant.  
 
Although not compelling, the 8% variation observed in PA AccT as a result of 
heart rate may be of more clinical interest. While this variable cannot be used 
as a primary and reliable predictor, considering heart rate when using PA 
AccT for the assessment of pulmonary hypertension may prove to be of 
clinical importance. Interestingly, cardiac output was not a significant predictor 
of PA AccT despite its heart rate influence. As expected, TAPSE was able to 
explain 25% of the variation in RV TDI S’ (and vice versa). Given both of 
these measures use longitudinal myocardial performance as a surrogate for 
pulmonary hypertension this relationship and predictive value was anticipated.    
 
In all instances, age was a significant contributor to echo derived parameters 
of pulmonary hypertension.  All echo parameters (TR Vmax, PA AccT, TAPSE 
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and RV TDI S’) indicated slightly increased risk of PHT with increasing age. 
This is consistent with McQuillan et al who reported age as the strongest 
predictor of RVSP, with an average increase in RVSP of 0.8mmHg per 
decade.84 Preceding studies based on smaller sample sizes have also 
reported an association between age and RVSP.93,94 
 
 
  4.7  Limitations  
 
As this was a retrospective clinical evaluation, a major limitation of this study 
was missing data. This was particularly evident in the assessment of PA AccT 
and RV TDI S’ where only 62% and 59% were recorded and available for 
measurement. Both of these parameters should arguably be attainable in 
almost all cases. As discussed, this most likely reflects measurement 
omissions and a lack of compliance with protocol rather than an inability to 
make an accurate measurement.   
  
Only 44% of TTEs were able to accurately estimate TR Vmax. The reduced 
ability to measure TR Vmax in only 44% was more likely a result of insufficient 
volume of tricuspid regurgitation and an inability to make an accurate 
measurement as failed spectral Doppler attempts were recorded. TTEs are 
performed in line with departmental, national and international guidelines and 
routine measurement of this parameter is deemed necessary for all studies. 
However, in some instances an estimate of TR Vmax may simply not have 
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been performed and some missing measurements may have been more likely 
to be collected in a prospective study performed by a single individual. 
 
The retrospective nature of this study precluded use of contrast to enhance 
the TR Vmax signal. This is a recognised and validated technique 
recommended by the American Society of Echocardiography.57 Rudski et al 
suggests a weak TR signal may be enhanced with agitated saline or blood-
saline contrast.57  
 
When comparing echo parameters to categories of pulmonary hypertension 
risk, it is important to consider that these categories have been based on 
research recommendations and evidence from the literature. They are 
therefore not representative of pulmonary hypertension as diagnosed using 
direct comparison with right heart catheterisation, the recognised gold 
standard. 
 
 
  4.8  Conclusion 
 
Within this sickle cell disease cohort, TR Vmax was measurable in less than 
half of all cases, suggesting TR Vmax is not a reliable, independent 
parameter to use in the diagnosis of PHT. When described using the PHT 
classification, only 25% of TTEs were consistent with intermediate or possible 
PHT (TR Vmax >2.6m/s).  
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PA AccT was more frequently measured than was TR Vmax (62% vs 44% of 
TTEs). Additionally this echo-derived marker of PHT was also able to identify 
a larger number of TTEs with intermediate or possible PHT according to the 
classification of risk. It therefore may prove beneficial to examine the accuracy 
and sensitivity of this parameter directly with right heart catheterisation, the 
recognised gold standard.  
 
TAPSE was the most measurable parameter with 91% of TTEs demonstrating 
a recordable measurement and RVTDI S’ was the least measurable (59%).  
 
These findings suggest that screening for PHT should include TR Vmax in 
combination with other echocardiographic measures, in particular PA AccT, 
which is more measurable and may prove beneficial in identifying the highest 
number of patients at risk of PHT.     
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CHAPTER 5 
 
_________________________________________ 
 
TRICUSPID REGURGITATION VELOCITY 
MAXIMUM (TR VMAX) AND OTHER 
ECHOCARDIOGRAPHIC PARAMETERS OF 
PULMONARY HYPERTENSION: Is there 
agreement and what if TR Vmax is not 
measurable?  
 
  5.1  Introduction 
 
In order to most accurately assess haemodynamic conditions, multiple 
parameters are measured during echocardiographic assessments. Reliance 
on one parameter alone may lead to problems with evaluation and 
interpretation, ultimately affecting clinical management.57,95 Despite this, TR 
Vmax, currently considered the mainstay echocardiographic measurement in 
the assessment of pulmonary hypertension, is often used in isolation. 
Moreover its accuracy, reliability and reproducibility remain in question.15-17  
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This study has confirmed that TR Vmax is not always measurable and that the 
indices PA AccT, TAPSE and RV TDI S’ are more frequently recordable and 
measurable. Gladwin et al assumed that if TR Vmax was not measurable the 
PA pressure must be normal.14 In order to test the validity of this assumption, 
we investigated how often echo parameters other than TR Vmax suggested 
PHT and the relationship between TR Vmax and the remaining echo 
parameters.  
 
 
  5.2  Objective 2 
 
The aim of this chapter was firstly, to test agreement between TR Vmax and 
PA AccT, TAPSE and RV TDI S’ to assess if any of these parameters could 
be reliably used as a surrogate for TR Vmax. Secondly, to determine whether, 
in the absence of TR Vmax, how often the remaining echo parameters, PA 
AccT, TAPSE and RV TDI S’, indicate PHT.  
 
 
  5.3 Methods 
 
As described in chapter 3 and 4, echo parameters were used to classify 
groups according to disease severity. These groups were normal, 
intermediate and possible PHT and form classification of risk Option A (table 
4.1). When frequency counts were less than five, this classification of risk 
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table could not be reliably used. Therefore categories were modified to allow 
for further statistical analysis by combining normal and intermediate groups, 
Option B (table 5.1) and combining intermediate and possible groups, Option 
C (table 5.2).  
 
Table 5.1. Option B: Modification of echo categories defining normal and intermediate groups combined, versus 
possible pulmonary hypertension (PHT).  
 
Abbreviations: TR Vmax = tricuspid valve regurgitation velocity; PA AccT = pulmonary artery acceleration time; 
TAPSE = tricuspid annular plane systolic excursion; RV TDI S’ = right ventricular tissue Doppler imaging systolic 
wave. 
 
 
Table 5.2. Option C: Modification of echo categories defining normal, versus intermediate and possible pulmonary 
hypertension (PHT) combined.  
 
 
 
Abbreviations: TR Vmax = peak tricuspid valve regurgitation jet velocity; PA AccT = pulmonary artery acceleration 
time; TAPSE = tricuspid annular plane systolic excursion; RV TDI S’ = right ventricular tissue Doppler imaging 
systolic wave. 	  	  	  
   
Category Classification TR Vmax 
(m/s) 
PA AccT 
(ms) 
TAPSE 
(cm) 
RV TDI S’ 
(m/s) 
1 Normal or  
Intermediate 
< 2.9 > 80 > 1.6 > 0.10 
2 Possible PHT > 2.9 < 80 < 1.6 < 0.10 
Category Classification TR Vmax 
(m/s) 
PA AccT 
(ms) 
TAPSE 
(cm) 
RV TDI S’ 
(m/s) 
1 Normal PHT < 2.6 > 105 >1.8 > 0.12 
2 Intermediate 
or Possible 
> 2.6 < 105 < 1.8 < 0.12 
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  5.4  Statistical Analysis  
 
The correlation between TR Vmax and PA AccT, TAPSE and RV TDI S’ was 
assessed. Spearman’s Rho statistic (non-parametric) and Pearson’s Rho 
(parametric) were used to assess correlation between continuous variables. 
According to discontinuous categorical variables (normal, intermediate, or 
possible PHT – Option A (table 4.1)) association was examined using counts 
and percentages and Chi Square Test. Where cells with expected counts less 
than five were obtained, Fisher’s Exact Test in conjunction with the 
classification of risk Option B (table 5.1) and Option C (table 5.2) were used. 
Continuous and categorical variable were compared using Kruskal-Wallis 
Tests for non parametric distributions and ANOVA for parametric distributions. 
Classification and regression tree (CART) was also used to investigate the 
relative influence of the remaining echo parameters in the prediction of TR 
Vmax, when TR Vmax was not measurable.85,86 Classification and regression 
trees allow the construction of prediction models from data. The models are 
obtained by recursively segregating the data and fitting a simple prediction 
model at each level of segregation.85,86 
 
  5.5  Results  
 
 5.5.1 TR Vmax compared to echo parameters using continuous 
  variables 
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Correlation between TR Vmax and other echo parameters was initially 
examined using Rho (r) and scatterplots. For TR Vmax and either PA AccT, 
TAPSE, or RV TDI S’ comparisons demonstrated very low to mild correlation 
(r<0.3 for all analyses; table 5.3) with scatterplots confirming this graphically. 
TR Vmax showed mild negative correlation with PA AccT (figure 5.1) with very 
low positive correlation for TR Vmax and either TAPSE or RV TDI S’ (figures 
5.2 and 5.3). 
 
Table 5.3. Correlation assessment: tricuspid regurgitation velocity maximum (TR Vmax) as a continuous variable 
compared to continuous variables pulmonary artery acceleration time (PA AccT), tricuspid annular plane systolic 
excursion (TAPSE), or right ventricular tissue Doppler imaging systolic wave (RV TDI S’). 
 
 
 
 
 
 
 
Abbreviations: TR Vmax = tricuspid valve regurgitation velocity; PA AccT = pulmonary artery acceleration time; TAPSE = 
tricuspid annular plane systolic excursion; RV TDI S’ = right ventricular tissue Doppler imaging systolic wave. 
 
Compared to 
TR Vmax 
Spearman’s Rho 
(r) 
Sig. 
P value 
PA AccT - 0.20 0.001 
TAPSE 0.01 0.055 
RV TDI S’ 0.15 0.016 
________________________________________________________________________________________ 
Echocardiographic measures of pulmonary hypertension and the prediction of end-points in sickle cell disease 	  
100 
  
 
Figure 5.1 Scatterplot demonstrating mild negative correlation (r = -0.2) between tricuspid regurgitation velocity 
maximum (TR Vmax) and pulmonary artery acceleration time (PA AccT).  
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Figure 5.2 Scatterplot demonstrating very low correlation (r = 0.01) between tricuspid regurgitation velocity maximum 
(TR Vmax) and tricuspid annular plane systolic excursion (TAPSE). 
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Figure 5.3 Scatterplot demonstrating very low correlation (r = 0.15) between tricuspid regurgitation velocity maximum 
(TR Vmax) and right ventricular tissue Doppler systolic wave (RV TDI S’). 
 
 
 5.5.2 TR Vmax compared to echo parameters using categorical 
  variables 
 
When assessed using categorical variables (option A (table 4.2), Chi Square 
proved inadequate with most assessments not meeting statistical 
assumptions (cells with expected counts less than five). Using classification of 
risk Option C (table 5.2,), an association between the categorical variables 
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was demonstrated when Chi square was repeated. This showed that of those 
assessments with TR Vmax in the ‘intermediate or possible PHT’ group, 50% 
were ‘intermediate or possible PHT’ for PA AccT.  This compared with 23% of 
assessments that demonstrated ‘intermediate or possible PHT’ for PA AccT 
but were normal for TR Vmax (Figure 5.4).  
 
There was no difference noted when TR Vmax was compared to categories of 
TAPSE or RV TDI S’ across any of the defined risk classification groups 
(options A, B and C) (Fisher’s Exact Test, p>0.05).  
 
 
Figure 5.4 Stacked bar chart demonstrating categories of tricuspid regurgitation velocity maximum (TR Vmax) versus 
categories of pulmonary artery acceleration time (PA AccT) (classification of risk Option C). 
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 5.5.3 TR Vmax compared to echo parameters using continuous 
  and categorical variables 
 
TR Vmax was significantly different across risk categories (Option A) for PA 
AccT. (Kruskal-Wallis Test p=0.000). Figure 5.5 shows a box and whisker plot 
demonstrating the variation in tricuspid regurgitation velocity maximum (TR 
Vmax) across categories of PA AccT. There was no significant difference in 
TR Vmax across the categories for TAPSE or RV TDI S’ (ANOVA p>0.05) 
(figures 5.6 and 5.7).  
 
 
 
Figure 5.5 Box and whisker plot demonstrating tricuspid regurgitation velocity maximum (TR Vmax) across 
categories of pulmonary artery acceleration time (PA AccT). Box: midline – median, top – third quartile, bottom – first 
quartile; Whiskers: minimum and maximum; circles: outliers. 
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Figure 5.6 Box and whisker plot demonstrating tricuspid regurgitation velocity maximum (TR Vmax) across 
categories of tricuspid annular plane systolic excursion (TAPSE). Box: midline – median, top – third quartile, bottom – 
first quartile; Whiskers: minimum and maximum; circles: outliers. 
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Figure 5.7 Box and whisker plot demonstrating tricuspid regurgitation velocity maximum (TR Vmax) across 
categories of right ventricular tissue Doppler imaging systolic wave (RV TDI S’). Box: midline – median, top – third 
quartile, bottom – first quartile; Whiskers: minimum and maximum; circles: outliers. 
 
 
 5.5.4 Comparison between the remaining echo parameters  
 
5.5.4.1 PA AccT vs TAPSE 
 
There was minimal correlation between PA AccT and TAPSE (Pearson’s 
Rho=0.1). When assessed using categorical variables as defined by cut offs 
in the classification of risk Option A and B (tables 4.1 and 5.1), Chi Square 
proved inadequate and did not meet statistical assumptions (cells with 
expected counts less than five). Classification of risk Option C (table 5.2) 
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showed no statistical significance using Fisher’s Exact test (p>0.05; p>0.999). 
When comparing continuous and categorical variables using ANOVA, there 
was no statistical difference (p>0.05; p=0.45). 
 
5.5.4.2 PA AccT vs RV TDI S’ 
 
There was very low correlation between PA AccT and TAPSE (Pearson’s 
Rho=0.03). In all three comparisons (Option A, B, C) Chi Square proved 
inadequate and did not meet statistical assumptions (cells with expected 
counts less than five). When comparing continuous and categorical variables 
using ANOVA there was no statistical difference noted (p>0.05; p=0.26). 
 
5.5.4.3 TAPSE vs RV TDI S’ 
 
There was moderate correlation between TAPSE and RV TDI S’ which was 
statistically significant (Pearson’s Rho= 0.5; p<0.000) (figure 5.8). 
Classification of risk Options A and B did not meet the statistical assumptions 
with cells with expected counts less than five. However, when assessing 
classification of risk Option C, there was a statistically significant difference 
between categories of TAPSE and RV TDI S’ when intermediate and possible 
PHT were combined and compared to the normal group (Kraskal-Wallis; 
p<0.000) (figure 5.9). When TAPSE was normal, RV TDI was largely also 
normal (78%). However when TAPSE was abnormal, the proportion of RV 
TDI S’ measurements which were also abnormal reduced to 28 (60%). Similar 
results were obtained when comparing continuous and categorical variables. 
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Using ANOVA, there was a statistical difference noted when comparing all 
three groups (p<0.000) (figure 5.10).  
 
 
 
 
Figure 5.8 Scatterplot demonstrating moderate correlation (r=0.5) between tricuspid annular plane systolic excursion 
(TAPSE) and tissue Doppler imaging of the right ventricle systolic wave (RV TDI S’). 
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Figure 5.9 Stacked bar chart demonstrating categories of tricuspid annular plane systolic excursion (TAPSE) across 
categories of tissue Doppler imaging right ventricular systolic wave (RV TDI S’) (classification of risk Option C). 
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Figure 5.10 Box and whisker plot demonstrating tricuspid annular plane systolic excursion (TAPSE) across 
categories of tissue Doppler imaging right ventricular systolic wave  (RV TDI S’). Box: midline – median, top – third 
quartile, bottom – first quartile; Whiskers: minimum and maximum; circles: outliers. 
 
 
 5.5.5 Echo parameters when TR Vmax was not measurable 
 
TR Vmax was not measurable in 559 (56%) of 1002 cases. Other echo 
parameters identified 150 (27%) TTEs as abnormal (intermediate or possible 
PHT) studies. Studies were abnormal as follows: PA AccT identified 101, 
TAPSE 38 and RV TDI S’ 78 (table 5.4). There were 196 TTEs identified as 
intermediate risk and a further 21 TTEs identified as having possible PHT, the 
highest risk group.  
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Table 5.4.  Echo parameters and the frequency of transthoracic echocardiography assessment (TTEs) 
identified as intermediate and possible pulmonary hypertension (PHT) when tricuspid regurgitation velocity 
maximum (TR Vmax) was not measurable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: TR Vmax = peak tricuspid valve regurgitation jet velocity; PA AccT = pulmonary artery 
acceleration time; TAPSE = tricuspid annular plane systolic excursion; RV TDI S’ = right ventricular tissue 
Doppler imaging systolic wave. 
 
 
Correlation and regression tree (CART) analysis showed that PA AccT 
had the greatest influence in predicting TR Vmax with a PA AccT <81ms 
predicting a TR Vmax of >2.85m/s (figure 5.11). This analysis also 
showed that if PA AccT was >81ms and RV TDI was <0.175, a TR Vmax 
of 2.6m/s could be predicted (figure 5.12).  
 
 TR Vmax  
Not Measurable 
Intermediate Possible Total Abnormal 
PA AccT 
(n=626) 
90 (14%) 11 (2%) 101 
TAPSE 
(n=916) 
33 (4%)  5 (0.5%) 38  
RV TDI S’ 
(n=593) 
73 (12%) 5 (8%) 78  
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Figure 5.11. CART analysis demonstrating the prediction of TR Vmax using PA AccT and other echo parameters. At 
each split of the tree, when the decision rule is true, move towards yes. When the rule is false, move towards no. i.e. 
PA AccT < 80.5ms is consistent with a TR Vmax > 2.8m/s. 
 
Abbreviations: TR Vmax = peak tricuspid valve regurgitation jet velocity; PA AccT = pulmonary artery acceleration 
time; TAPSE = tricuspid annular plane systolic excursion; RV = right ventricular tissue Doppler imaging systolic wave. 
 
 
PA_AccT >= 80.5
RV < 0.175
PA_AccT >= 104
TAPSE >= 1.85
TAPSE < 2.65
RV < 0.155
PA_AccT >= 150
1.94 2.25
2.42
2.34
2.42
2.39
2.59
2.85
yes no
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Figure 5.12. CART analysis demonstrating the prediction of TR Vmax using PA AccT and other echo parameters. At 
each split of the tree, when the decision rule is true, move towards yes. When the rule is false, move towards no. i.e. 
PA AccT > 80.5ms and RV TDI S’ < 0.175 ms is consistent with a TR Vmax > 2.6m/s. 
 
Abbreviations: TR Vmax = peak tricuspid valve regurgitation jet velocity; PA AccT = pulmonary artery acceleration 
time; TAPSE = tricuspid annular plane systolic excursion; RV = right ventricular tissue Doppler imaging systolic wave. 
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  5.6  Discussion 
 
At best, there was only mild correlation between TR Vmax and the remaining 
echo-derived markers of PHT (PA AccT, TAPSE and RV TDI S’). Based on a 
combination of bivariate statistical analyses, there was no single echo 
parameter that was statistically correlated with TR Vmax and could be used 
consistently as a surrogate for TR Vmax.  
 
Bivariate analysis demonstrated an association between TR Vmax and PA 
AccT as categorical variables. Patients with intermediate or possible PHT on 
TR Vmax were more likely to have intermediate or possible PHT when 
assessed using PA AccT.  Clinically, this means as TR Vmax gets higher 
there is more likely an association between TR Vmax and PA AccT. This may 
not have been evident in the correlation because the association may be non-
linear, and the point at which the association became more apparent was well 
defined by the ranges of classification of risk option C.  
 
Comparison between variables demonstrated a moderate correlation between 
TAPSE and RV TDI S’. This relationship was anticipated given both 
techniques are based on right ventricular myocardial performance. These 
parameters (TAPSE and RV TDI S’) however showed a significant difference 
when analysed as categorical variables. This means that the distribution of 
TTEs classified as ‘normal’ and ‘intermediate and possible PHT’ varied 
between the echo parameters suggesting a lack of association. This 
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discrepancy is in agreement with suggestions by Li et al (2015) who found 
right ventricular systolic function correlated with RV TDI S′, but not with 
TAPSE. TAPSE and RV TDI S’ are routinely used to assess the longitudinal 
contractility of the right ventricle. While simple to apply and measure, both 
TAPSE and RV TDI S’ share some inherent limitations that are mostly a result 
of being restricted to the longitudinal function of the RV free wall whilst 
disregarding the contribution of the interventricular septum and the RVOT 
and, on occasions, the LV.96-98 Additionally both TAPSE and RV TDI S’, 
although recognised as markers of PHT, may be reduced with intrinsic 
myocardial abnormalities such as global or regional right ventricular 
dysfunction, even with a normal PA pressure. 57,99,100 
 
A significant finding of this chapter was related to echo parameters when TR 
Vmax was not measurable. There were 101 TTEs with abnormal PA AccT, 38 
TTEs with an abnormal TAPSE and 78 TTEs with abnormal RV TDI S’.  In a 
seminal US study, pulmonary-artery pressures were assumed to be normal in 
patients with trace or no tricuspid regurgitation but our results show that this 
assumption is not valid.14 This finding has been supported in a previous study 
which demonstrated that in 10% of invasively proven PHT, the diagnosis can 
be missed by estimation of RVSP using echocardiography alone, due to a 
lack of tricuspid valve insufficiency.101 Further to this, the use of PA AccT in 
clinical practice, especially for patients with unmeasurable TR has been 
recommended.102 The results of the current study therefore suggest that PA 
AccT, which is attainable in most patients, may provide a better screening tool 
for potential PHT within the sickle cell population and should therefore be 
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further investigated for accuracy, sensitivity and specificity in relation to 
clinical end-points. 
 
CART analysis showed PA AccT was the single best predictor of TR Vmax, a 
clinically significant finding from this study. The analysis demonstrated a PA 
AccT <81ms corresponded to a TR Vmax of 2.85m/s. This was consistent 
with two other studies which reported that PA AccT <93ms and <100ms 
respectively were indicative of a higher probability of pulmonary 
hypertension.60,103 
 
 
  5.7  Limitations  
 
Only a small number of subjects within this patient cohort had a significantly 
elevated TR Vmax, shortened PA AccT or reduced RV TDI S’ or TAPSE 
consistent with a possible PHT risk. This in itself needs to be considered 
when extrapolating and interpreting findings.   
 
Due to the small number of TTEs in the possible PHT groups, the 
classification of risk was modified to allow for categorical statistical 
comparison. However, by combining the intermediate and possible PHT 
groups, there may have been a dilution in the effect of those at possible PHT 
risk. Similarly, it is important to recognise that, although comparisons between 
________________________________________________________________________________________ 
Echocardiographic measures of pulmonary hypertension and the prediction of end-points in sickle cell disease 	  
117 
echo parameters and risk groups are being drawn, there is no gold standard 
for comparison. 
 
 
  5.8  Conclusion 
 
Within this sickle cell disease cohort, no single echo marker could reliably 
substitute for TR Vmax. However, when TR Vmax was not measurable, the 
remaining echo parameters identified additional TTEs assessments with 
intermediate or possible PHT with PA AccT identifying the highest number of 
abnormal results. CART analysis showed that PA AccT best indicated TR 
Vmax. Future work should explore the accuracy of PA AccT for predicting 
end-points.  
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CHAPTER 6 
 
_________________________________________ 
 
END-POINTS AND ECHO PARAMETERS: Is 
there an association? Is a redefinition of 
markers of PHT based on a combination of echo 
markers a better predictor of PHT?  
 
  6.1  Introduction 
 
Elevated pulmonary pressure derived using TR Vmax has been shown to 
correlate with pulmonary hypertension on right heart catheterisation.71 
However, it is not practical to perform right heart catheterisation on all patients 
nor is it possible to measure TR Vmax on all patients. In addition to this, the 
relationship between pulmonary hypertension established on RHC and 
morbidity and mortality associated with SCD related pulmonary hypertension 
is not well understood. 
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This study has shown that PA AccT, TAPSE and RV TDI S’ are more 
measurable than TR Vmax. Further to this, in the absence of TR Vmax, PA 
AccT, TAPSE and RV TDI S’ are able to identify patients potentially at risk of 
pulmonary hypertension. However there remains a dearth of research into the 
diagnostic potential of combining echo parameters in the identification of 
pulmonary hypertension and how effective echo parameters are in the 
prediction of events such as death and sickle cell crisis requiring hospital 
admission. 
 
 
  6.2 Objective 3 
 
The aims of this chapter were threefold: 1) to determine whether TR Vmax, 
PA AccT, TAPSE and RV TDI S’ were associated with end-points as defined 
by death, pulmonary hypertension (PHT) on right heart catheterisation (RHC) 
and sickle crisis requiring hospital admission; 2) in the absence of TR Vmax, 
assessment of the association between end-points and the remaining echo 
parameters; 3) to test whether a redefinition of pulmonary hypertension based 
on a combination of echo markers was a better predictor of pulmonary 
hypertension than using TR Vmax alone.   
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  6.3 Methods  
 
As previously described in Methodology and Research Design (chapter 3), 
echocardiographic, clinical, laboratory and demographic data were collected.  
 
In chapter 6, further comparisons were made between these data and end-
points. End-points were defined as: 1) death; 2) mean pulmonary artery 
pressure >25mmHg on right heart catheterisation (RHC); 3) sickle cell crisis 
requiring hospital admission. Death and PHT on RHC were necessarily 
counted only once. Repeat admissions were counted as more than one end-
point provided they occurred more than one year apart. The criterion is 
outlined in table 6.1.  
 
Table 6.1 Criteria for end-points (death, pulmonary hypertension (PHT) on right heart catheterisation (RHC), and 
sickle cell crisis requiring hospital admission). 
 
End-Point Criteria 
1. Death 
2. Pulmonary hypertension on RHC with a mean >25mmHg 
3. Sickle cell crisis requiring hospital admissiona 
 
 
  6.4  Statistical analysis 
 
Comparisons between groups were demonstrated using counts and 
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percentages. Fisher’s Exact Test was also used to compare categories of 
echo parameters with end-points (classification of risk options A, B and C). 
The association between echo parameters as continuous variables and end-
points was assessed using Kruskal-Wallis for non parametric distributions and 
recorded using median and interquartile range. The association between the 
remaining echo parameters (as continuous variables) and end-points was 
assessed using ANOVA for parametric distributions. Results were recorded 
using mean and standard deviation. 
 
Fisher’s Exact test was used for categorical comparisons, and Krusal-Wallis 
and Mann U Test were used for continuous versus categorical comparisons. 
Echo parameters were also assessed for their specificity and sensitivity. This 
was performed using classification of risk options B and C. 
 
When assessing a redefinition of pulmonary hypertension, binary logistic 
regression was used to predict a categorical variable as defined by combined 
end-points from a set of predictor variables (predictive risk). Echo parameters 
were used as predictor variables. In addition to this, other demographic, 
clinical and laboratory results were used as predictor variables.   
 
Boosted regression trees (BRT) were used to identify non-linear sets of 
variables for the prediction of end-points. This sophisticated form of 
regression draws on insights and techniques from both statistical and 
machine learned traditions.88 The BRT approach uses boosting techniques to 
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combine large numbers of relatively simple tree models adaptively to optimise 
predictive performance.88  
   
 
  6.5 Results 
 
 6.5.1  General results 
 
There were 143 end-points recorded from 125 patients: 135 hospital 
admissions, 2 PHT on RHC (from a total of 8 RHC performed) and 6 deaths. 
The mortality rate was extremely low (<1%).  The mean follow up time was 
939 days (SD: 546).  
 
Possible PHT could be defined by up to 4 separate echocardiographic criteria; 
TR Vmax, PA AccT, TAPSE, RV TDI S’.  There were 66 TTE positive by one 
criterion. There were a further five TTEs positive by two criteria and one by 
four criteria.  
 
There was no statistical difference in the number of patients with one or more 
abnormal echo parameters who had end-points (10 (7%) compared to those 
without end-points (48 (6%); p=0.39). Although there appears to be a variation 
in absolute number (10 vs 48), this is a consequence of a smaller proportion 
of total patients with end-points compared to those without end-points.    
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 6.5.2 Comparing end-points with TR Vmax 
 
Figure 6.1 compares TR Vmax derived categories of PHT with end-points.  
There were 28 TTE studies where TR Vmax indicated possible PHT. Of 
these, 3 (11%) had end-points. There were 83 TTE studies where TR Vmax 
indicated intermediate risk of PHT.  Of these, 13 (16%) end-points were 
recorded. For normal TR Vmax (288) and end-points, there were 44 (13%) 
recorded end-points.  
 
 
Figure 6.1 Cluster bar chart comparing tricuspid regurgitation velocity maximum (TR Vmax) derived categories with 
end-points. 
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When TR Vmax was defined using categorical variables (Option A (table 
4.1)), Chi Square proved inadequate with most assessments not meeting 
statistical assumptions (cells with expected counts less than five). However 
using Options B and C (tables 5.1 and 5.2), statistical analysis demonstrated 
no significant difference between groups with and without end-points (Option 
C - Fisher’s Exact Test; p=0.75). Similarly there was no significant difference 
in the distribution of TR Vmax across categories with and without end-points 
(Kruskal-Wallis p=0.423). The median for those with end-points was 2.2m/s 
(IQR: 0.5) compared with 2.3m/s (IQR: 0.4) for those without end-points 
(figure 6.2). 
 
 
Figure 6.2 Box and whisker plot comparing tricuspid regurgitation velocity maximum  (TR Vmax) with and without 
end-points. Box: midline – median, top – third quartile, bottom – first quartile; Whiskers: minimum and maximum; 
circles: outliers. 
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 6.5.3 Comparing end-points with the remaining echo parameters 
 
Of the 25 TTE with possible PHT using PA AccT (<80ms), 9 (36%) had end-
points. Of 154 intermediate (PA AccT 80-105ms) TTE, 25 (16%) had end-
points.  
 
Of the 13 TTE studies in which PHT was categorised as possible PHT using 
TAPSE (<1.6cm), only 1 (8%) end-point was noted. Of the intermediate group 
(TAPSE 1.6-1.8cm), 7 (10%) from 70 TTEs corresponded with end-points.  
 
Of the 10 TTE studies in which PHT was categorised as possible PHT using 
RV TDI S’ (<0.10m/s), there were 4 (40%) end-points noted. Of the 
intermediate group (RV TDI S’ 0.10-0.12ms), 22 (1%) from 137 TTEs 
corresponded with end-points. Table 6.2 summarises these findings. 
 
Fisher’s Exact test demonstrated no significant difference in PA AccT, TAPSE 
or RV TDI S’ for groups with or without end-points (p>0.05). Similarly Mann 
Whitney U tests showed no significant association between PA AccT, TAPSE 
and RV TDI S’ when compared to end-points (p>0.05).  
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Table 6.2 The number of end-points per echo parameters as categorised by intermediate and possible pulmonary 
hypertension (PHT) risk. Note: Tricuspid regurgitation velocity maximum (TR Vmax) has not been included as the 
analysis focused on end-points and the remaining echo parameters. For TR Vmax and end-points analysis refer to 
section 6.5.2.  
 
 
Parameter Category End-point No End-point 
PA AccT Intermediate 25 (16%) 129 (84%) 
 Possible 9 (36%) 16 (64%) 
TAPSE Intermediate 7 (10%) 63 (90%) 
 Possible 1 (8%) 12 (92%) 
RV TDI S’ Intermediate 22 (1%) 115 (99%) 
 Possible 4 (40%) 6 (60%) 
 
Abbreviations: PA AccT = pulmonary artery acceleration time; TAPSE = tricuspid annular plane systolic 
excursion; RV = right ventricular tissue Doppler imaging systolic wave. 
 
 6.5.4 Comparing echo parameters with death and hospital 
 admission independently  
 
There were six patients who died; 3 with abnormal TR Vmax, 4 with abnormal 
PA AccT, 1 with abnormal TAPSE and 2 with abnormal RV TDI S’. Table 6.3 
provides details regarding echo parameters for each individual patient who 
died. 
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Table 6.3. Patients who died and their corresponding echo parameters. Intermediate and possible risk is highlighted 
in red. Abbreviations: N/A = missing data.  
 
Patient TR Vmax 
(m/s) 
PA AccT 
(ms) 
TAPSE  
(cm) 
RV TDI S’ 
(m/s) 
1 2.2 78 2 0.15 
2 N/A 125 2.5 N/A 
3 2.8 60 N/A N/A 
4 N/A  N/A 2.1 0.12 
5 2.7 104 2.4 0.10 
6 3.2 76 1.5 0.07 
 
Abbreviations: TR Vmax = peak tricuspid valve regurgitation jet velocity; PA AccT = pulmonary artery 
acceleration time; TAPSE = tricuspid annular plane systolic excursion; RV TDI S’ = right ventricular tissue 
Doppler imaging systolic wave. 
 
 
When assessing those with end-points, there was no significant difference in 
TR Vmax between those who died and those who did not (Fisher’s Dot test, 
p=0.06). Similarly there was no significant difference in TR Vmax for those 
with hospital admission compared to those without hospital admissions 
(Fisher’s Dot test, p=0.5). This was also the case for variables TAPSE and RV 
TDI S’ (Fisher’s Dot test >0.05). Fisher’s Dot Test demonstrated a significant 
difference between those who died and those who did not when using PA 
AccT (p=0.003). There was also a significant difference in the PA AccT when 
assessing those with and without hospital admissions (p=0.027).  
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Two patients were identified as having PHT on RHC. Neither of these patients 
had a recordable TR Vmax. However on both occasions PA AccT was 
<88ms, consistent with possible PHT. 
 
 6.5.5 End-points and echo parameters:  
  sensitivity and specificity 
 
Using classification of risk (option B: normal and intermediate combined 
versus possible PHT), the sensitivity of TR Vmax in the prediction of end-
points was 93% with a specificity of only 5%. For PA AccT using option B, 
sensitivity and specificity were 97% and 9%, respectively.  
 
When using the classification of risk (option C: normal versus intermediate 
and possible PHT combined), the TR Vmax sensitivity was 75% with a 
specificity of 26%. Similarly for PA AccT using option C the sensitivity was 
73% and specificity of 34%. The sensitivity and specificity for TAPSE and RV 
TDI S are included in table 6.4.  
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Table 6.4 Sensitivity and specificity for echo parameters. 
Echo 
parameter 
Option A Option B 
Sensitivity 
(%) 
Specificity 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
TR Vmax 93 5 75 26 
PA AccT 97 9 73 34 
TAPSE 98 0.7 90 6 
RV TDI S’ 99 4 76 29 
 
Abbreviations: TR Vmax = peak tricuspid valve regurgitation velocity; PA AccT = pulmonary artery 
acceleration time; TAPSE = tricuspid annular plane systolic excursion; RV = right ventricular tissue Doppler 
imaging systolic wave. 
 
 6.5.6 Echo parameters compared with end-points in the absence 
  of TR Vmax 
 
When TR was not measurable, the remaining echo parameters identified 
additional abnormal TTEs (chapter 5, section 5.5.5, table 5.4)). When 
assessing TTEs with no measurable TR Vmax and an association with end-
points, the results were as follows: 24 TTEs positive for one echo criteria, 3 
TTEs positive for two echo criteria, and 0 TTEs positive for three echo criteria. 
There were 62 TTEs with no measurable TR Vmax and an association with 
end-points that were considered normal by echo criteria (table 6.5).  
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Chi square was used to compare those with and without echo abnormalities 
with those with and without end-points but no significant difference was 
observed (Chi Square; p>0.05).  
 
Table 6.5 Transthoracic echocardiography examinations (TTEs) with no measurable tricuspid regurgitation velocity 
maximum (TR Vmax) and an association with end-points categories by number of abnormal echo criteria.  
 
 
 
  
 
 
 
 
 6.5.7 A redefinition of pulmonary hypertension 
 
Examination of a combination of echo-derived parameters (TR Vmax, PA 
AccT, TAPSE and RV TDI S’) as continuous variables was not statistically 
reliable for the overall prediction of end-points (binary logistic regression, 
omnibus test, P=0.062). However the p-value may be suggestive of a 
predictive capability. PA AccT and TAPSE were found to be the most 
significant predictors. Yet, when the logistic regression was repeated with 
these two predictive variables alone, there was no significant difference noted 
(binary logistic regression, omnibus test p=0.4). PA AccT had the lowest p-
value (p=0.08) suggesting it is relatively stronger than all other individual 
measures (TR Vmax: p=0.6; TAPSE: p=0.4; RV TDI S’: p=0.3).  
Number of abnormal 
echo criteria 
Number of TTEs 
0 62 
1 24 
2 3 
3 0 
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When analysing other clinical parameters, inclusion of age, pulse, O2 
saturations, and haemoglobin in the logistic regression significantly improved 
prediction of end-points (binary logistic regression: p=0.026).  
 
Boosted regression tree (BRT) analysis of the prediction of end-points also 
showed that PA AccT had at least a 6-fold greater influence when compared 
to the remaining echo parameters (figure 6.3).  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
Figure 6.3. Boosted regression tree (BRT) analysis demonstrating pulmonary artery acceleration time (PA AccT) with 
a 6-fold greater influence in end-points when compared to other transthoracic echocardiography (TTE) parameters. 
BRT analysis identifies non linear sets of variables that best predict end-points. 
 
Abbreviations: TR Vmax = peak tricuspid valve regurgitation jet velocity; PA AccT = pulmonary artery acceleration 
time; TAPSE = tricuspid annular plane systolic excursion; RV = right ventricular tissue Doppler imaging systolic wave. 
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  6.6 Discussion 
 
The results of this study show that TR Vmax does not predict end-points but 
that PA AccT may be more useful.  
 
When focusing only on individuals who experienced end-points, PA AccT was 
able to identify a greater proportion of individuals in the possible PHT risk 
group (36%) compared to TR Vmax (11%). More specifically, for the small 
number of patients who died, PA AccT was recorded as abnormal in more 
individuals than TR Vmax and this was statistically significant. Clinically, this 
means that PA AccT is not only more measurable than TR Vmax but it also 
has the potential to identify more patients likely to die, likely to be identified as 
having PHT on RHC, or likely to be admitted to hospital as a result of sickle 
cell crisis.  
 
The study cohort had a very low mortality rate with only 6 (<1%) deaths.  This 
finding was similar to a recent French study (2%) but lower than other US 
based studies.12-14 These differences are likely due to case-mix and the 
availability of hospital and community care.  
 
There were only two individuals who were found to have pulmonary 
hypertension on RHC (mean >25mmHg). TR Vmax was not measured in 
either. However in both patients PA AccT was <88ms consistent with possible 
PHT. This is supported by findings from Tousignant et al who found a 
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transoesophageal echocardiography (TOE) derived PA AccT of 90 ms was 
associated with elevated pulmonary artery pressure and pulmonary vascular 
resistance.104  
 
PA AccT demonstrated the best sensitivity and specificity balance of the four 
echo parameters. The sensitivity was 73%, similar to findings by Dabestani et 
al who reported a sensitivity of 78%.60 However when compared with other 
studies (up to 100%), the specificity for our study was much lower (34%). This 
may be related to the decision to combine risk groups and potential dilution of 
results to enable statistical analysis. Nevertheless the effects of a lower 
specificity need to be considered if this parameter was to be utilised in clinical 
practice.  
 
Using a combination of echo parameters provided no greater benefit to end-
point prediction. However analysis using Boosted Regression Trees (BRT) 
demonstrated PA AccT had a greater than 6-fold influence in the prediction of 
end-points compared to the other echo parameters. To our knowledge this is 
the first use of BRT to analyse this kind of relationship. Thus formal 
comparisons with previous research cannot be drawn.  
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  6.7  Limitations 
 
The major limitation of this comparison was the small number of patients who 
died or underwent right heart catheterisation positive for PHT. This means 
that interpretation has been based on a limited number of high risk patients 
with only a small number of events. This may have biased study conclusions. 
 
Further to this, it was not possible to assess risk based on death and PHT on 
RHC alone. In this study, we also used sickle cell crisis requiring hospital 
admission as an end-point. Although this may mean that the strength of the 
combined end-point is weakened compared to other studies, the addition of 
hospital admissions is quite novel and may have returned findings which have 
not been thoroughly investigated previously.  
 
One patient who died demonstrated abnormal echo results across all four 
echo parameters. This patient had multiple co-morbidities and was chronically 
unwell. Although the death may have been a consequence of pulmonary 
hypertension this cannot be definitively determined and could equally been 
attributed to severe left and right ventricular failure. In additional to this, details 
regarding hospital admission dates were unavailable for 12 patients. This may 
have biased follow up data.  
 
For this specific study sample, logistic regression proved a poor predictor as it 
was unable to classify groups or perform prediction accurately. There is some 
argument that weighted samples would have improved the predictive value of 
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the logistic regression by classifying the smaller groups. However this would 
have come at the expense of degradation in the overall correct 
classification.105 As such sample weighting has not been performed. 
 
 
  6.8  Conclusion 	  
Within this sickle cell disease cohort, a combination of echo measures did not 
predict end-points better than single measures. However PA AccT was 6-fold 
more useful in the prediction of end-points and demonstrated a better 
sensitivity and specificity balance compared to the other echo markers. 
Furthermore, PA AccT was useful in the identification of individuals at risk 
when TR Vmax was not measureable. 
 
These findings suggest that TR Vmax should not be used as an isolated 
predictor of end-points. It further suggests that PA AccT, which is more 
measureable than TR Vmax, is the most effective predictor for end-points 
particularly in relation to sickle cell crisis requiring hospital admission. 
Echocardiography based sickle cell screening should therefore include PA 
AccT in routine practice as it may prove beneficial in identifying the highest 
number of patients at risk of sickle cell related end-points.     
 
________________________________________________________________________________________ 
Echocardiographic measures of pulmonary hypertension and the prediction of end-points in sickle cell disease 	  
136 
CHAPTER 7 
 
_________________________________________ 
 
DISCUSSION, LIMITATIONS AND 
CONCLUSIONS 
 
 
  7. 1 Discussion 
 
Within this retrospective study of adult patients with sickle cell disease, we 
found that TR Vmax, recognised as the mainstay non-invasive parameter for 
the diagnosis of pulmonary hypertension, was measureable in less than half 
of our cohort. We found PA AccT was more measurable and also a more 
reliable predictor of SCD end-points.  
 
Current recommendations from the American Thoracic Society (ATS) suggest 
screening SCD patients for PHT using TR Vmax derived on echocardiography 
every 1-3 years.106 In light of our findings, we question the diagnostic benefit 
of using TR Vmax alone. We found echocardiography derived TR Vmax was 
not a reliable measurement and was not predictive of sickle cell related end-
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points.  
 
It is thus important to consider how the results of current transthoracic 
echocardiography examinations are being used in the management of 
patients. It is hypothesised that ‘borderline’ TR Vmax findings in conjunction 
with the presence of symptoms and other clinical data are used to initiate and 
expedite treatment with exchange transfusions, Hydroxycarbamide or other 
intensifying treatments for sickle cell patients. With this in mind, the 
controversy surrounding the use of a TR Vmax of 2.5m/s for the identification 
of PHT in SCD must be noted.  Although the ATS recommend TR Vmax of 
2.5m/s as a marker of possible pulmonary hypertension, they too remark on 
an improved specificity when a TR Vmax of at least 2.88m/s is used. In line 
with this, the American Society of Echocardiography considers a TR Vmax of 
2.8 or 2.9m/s to be indicative of PHT.57 We therefore suggest that a TR Vmax 
threshold of no less than 2.6m/s, where measurable, be used as a potential 
indicator of PHT.  
 
Given these research findings, further exploration of the usefulness of PA 
AccT in the identification of pulmonary hypertension and sickle cell disease 
end-points should be undertaken. PA AccT is more measurable and should 
be attainable in almost all TTE examinations. This reliable and powerful non-
invasive echo derived parameter could provide baseline measures as well as 
serving as a marker for change. Current research has suggested that a PA 
AccT greater than 120-130ms can exclude PHT with almost 100% accuracy.64 
Similarly PA AccT of less than 100ms can suggest PHT with 78% sensitivity.60 
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This indicates that PA AccT could be used as an adjunct to clinical 
parameters.  Enforcing a more robust definition of SCD PHT by combining TR 
Vmax with a higher threshold of >2.6m/s and PA AccT <105ms with 
symptoms and other clinical findings may prove advantageous for individuals 
with sickle cell disease. 
 
As part of this study patients who experienced a sickle cell crisis within the 
four weeks preceding transthoracic echocardiography were excluded as it 
was felt that this would deliver falsely elevated TR Vmax measurements. This 
is supported by the ATS who recommend a screening echocardiography 
assessment should not be performed within four weeks of an acute chest 
crisis, or within two weeks of a vaso-occlusive crisis.106 In this study, analysis 
of steady-state patients provided an evaluation of patients who were clinically 
stable and these findings are thought to be useful as they are representative 
of the sickle cell patient population presenting for routine clinic appointments 
and echocardiography examinations.  
 
 
  7.2  Considerations 
 
As part of our literature review, we noted that there was international variation 
in recommendations regarding methods for measurement of PA AccT. The 
British Society of Echocardiography (BSE) recommends measurement from 
the onset of pulmonary flow to peak pulmonary flow.59 This was the method 
employed in this investigation. In contrast, a mainstay guideline and 
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recommendation paper released by the American Society of 
Echocardiography (ASE) describes measurement of the PA AccT from the Q 
wave on the electrocardiogram (ECG) to the peak pulmonary flow.57 It is 
postulated that using a PA AccT performed using the latter approach (ASE 
recommendation) may mask pulmonary hypertension due to a prolonged 
interventricular contraction time (IVCT) secondary to RV dyssynchrony. In 
order to limit inter-operator variability, clear and descriptive nationally and 
internationally accepted guidelines regarding the technical approach to this 
measurement should be developed and published. 
 
N-terminal brain natriuretic peptide is used in the detection, diagnosis and 
evaluation of heart failure severity. Moreover, biomarkers such as brain 
natriuretic peptide (BNP) and NT-proBNP may be instrumental in uncovering 
early diagnoses of PHT and as such may be a potentially influential clinical 
biomarker within this population.107 An association between increased TR 
Vmax and higher levels of NT-proBNP has also been reported.92 Similarly a 
NT-proBNP level higher than 160 pg/ml was shown to be a major and 
independent predictor of mortality.5 Based on these findings, the American 
Thoracic Society highlight NT-proBNP as an independent risk factor in 
mortality for adult patients with PHT.106 In our study, we were unable to make 
comparisons between echo markers of pulmonary hypertension, end-points 
and N-terminal pro-brain natriuretic peptide (NT-pro BNP). Unfortunately, 
within our tertiary centre prior to 2014, NT-pro-BNP was primarily used in the 
assessment of heart failure and was not available for use in Haematology 
departments. In prospective studies NT-pro-BNP should be considered for 
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patients who are young and healthy with borderline echocardiography findings 
and only mild symptoms. Aside from diagnosis, elevated NT-pro-BNP levels 
may also be useful in guiding treatment and follow up.107 
 
Only a limited number of patients underwent six-minute walk tests (6MWT). It 
was therefore not included in our analysis. 6MWT has been showed to be 
important when assessing individuals with PHT. Parent et al used a six-
minute walk distance (6MWD) of less than 333m as an indicator for requiring 
RHC.13 More recently Agha et al demonstrated an independent association 
between TR Vmax and abnormal 6MWT results and encouraged the use of 
6MWTs as a non-invasive adjunct tool in the assessment of functional 
capacity of SCD patients with elevated TR Vmax.108 Further exploration into 
the use of NT-pro-BNP and 6MWT in conjunction with echo parameters (TR 
Vmax, PA AccT), clinical parameters and patient symptoms is encouraged in 
future studies. 
 
 
  7.3  Limitations 
 
Limitations of this research have been previously highlighted within each 
thesis chapter. In addition to these, some supplementary considerations are 
addressed. In this study formal assessment of the reproducibility of 
echocardiographic markers was not provided. Inter-operator and intra-
operator variability are important considerations in the synthesis of diagnostic 
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information and should be examined prior to the implementation of changes in 
clinical practice.  
 
The influence of obesity in the estimation of TR Vmax, PA AccT, TAPSE, RV 
TDI S’ was not assessed. As this study was retrospective and weights were 
not recorded in clinical reviews, this information was not available for 
comparison. Obesity has been shown to influence TR Vmax and as such it 
would have been of interest to examine the impact of obesity on TR Vmax 
and the remaining echo parameters.  
 
Although there were 504 patients in this study, there were 1002 
echocardiograms. Additionally, some patients had multiple hospitalisations.  
This means there may be some degree of correlation between observations 
and potential for bias as patients who were sicker were more likely to have an 
increased number of echocardiograms and/or hospital admissions.  
 
 
 
  7.4 Conclusions  
 
In this retrospective tertiary referral study, it was confirmed that TR Vmax was 
not measurable in all patients and was only reliably measured in less than half 
of all TTE examinations. We found that no single echo marker could be used 
as a surrogate for TR Vmax but PA AccT was the best predictor of TR Vmax. 
In the absence of TR Vmax, PA AccT was able to identify the highest number 
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of additional TTEs consistent with intermediate or possible risk of PHT. In the 
prediction of end-points, PA AccT demonstrated a 6-fold greater influence 
when compared to the remaining echo parameters. PA AccT also 
demonstrated the best balance of sensitivity and specificity. However using a 
combination of echo parameters provided no better prediction of end-points. 
These findings support the implementation of PA AccT combined with TR 
Vmax in the screening and identification of individuals with pulmonary 
hypertension related end-points associated with SCD.  
 
 
  7.5 Future Developments 
 
Prospective research should focus on evaluating the benefit of PA AccT in the 
prediction of mortality and other end-points including PHT on RHC in the SCD 
population. In addition to this, a combination of echocardiographic, clinical and 
physiologic markers (i.e. NT-pro-BNP and 6-minute walk tests) may prove 
beneficial in identifying asymptomatic patients at risk of pulmonary 
hypertension and mortality.  
 
In light of the limitations of echocardiography, it is important to consider the 
benefits of other imaging modalities. Magnetic resonance imaging (MRI) is 
better than echo for the assessment of volumes and mass. However it is very 
difficult to obtain an accurate estimation of pulmonary pressures using MRI.  A 
recent study suggested maladaptive RV remodelling in SCD patients with 
PHT could be identified using cardiac magnetic resonance (CMR) imaging. 
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The study concluded RV dysfunction derived using CMR independently 
predicted higher mortality in sickle cell disease.109 Consequently, the influence 
of CMR combined with echocardiography, biomarkers and physiologic 
parameters in the diagnosis and monitoring of PHT in the SCD population 
would be useful.107  
 
Currently, there is innovative research underway into genomic biomarkers of 
SCD. Desai and colleagues have investigated peripheral blood cell–derived 
gene signatures for an elevated TR Vmax in SCD.110 They highlight 
ADORA2B and GALNT13 as potential candidate genes and suggest that 
using these biomarkers, elevated TR Vmax can be predicted with 100% 
accuracy.110 It would be useful to correlate these novel targets with PA AccT, 
end-points and symptoms consistent with pulmonary hypertension in a large 
scale prospective study of sickle cell disease patients.  
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APPENDIX A1  
List of parameters for collection 
Demographic Parameters 
• Age 
• Sex 
• Race 
 
Clinical Parameters 
• Systolic blood pressure 
• Diastolic blood pressure 
• Pulse rate 
• Pulse oximetry 
 
Medical History 
• History of respiratory disease 
• History of pulmonary emboli 
• Number of hospital admissions 
• Reason for hospital admissions 
• Blood transfusion history 
• Symptoms of chest pain 
• Medical therapy 
• Confounding causes of pulmonary hypertension including LV  
dysfunction, CAD, valve disease, asthma, smoker, COPD. 
 
Echocardiographic Parameters 
• Right ventricular size (RV size) 
• Peak tricuspid regurgitation velocity (TR Vmax) 
• Pulmonary valve acceleration time (PV AT) 
• Mean pulmonary pressure (using end-diastolic pulmonary  
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 regurgitation where possible) (MPAP) 
• Pulmonary valve velocity time integral (PV VTI) 
• Pulmonary vascular resistance (ratio of peak TR to PV VTI) 
• Left atrial area (LA area) 
• Right atrial area (RA area) 
• Tricuspid annular plane systolic excursion (TAPSE) 
• Right ventricular tissue Doppler imaging (RV TDI) 
• Inferior vena cava collapsibility (IVC) 
• Left ventricular outflow tract diameter (LVOT D) 
• Left ventricular outflow tract velocity time integral (LVOT VTI) 
 
Additional testing 
• Computed tomography 
• Right heart catheterisation including pulmonary capillary wedge 
    pressure and pulmonary vascular resistance 
 
Laboratory Markers 
• Full blood count 
• Urea and Electrolytes 
• Liver function tests 
• Lactate dehydrogenase 
• Reticulocyte count 
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APPENDIX A2 
	  
Department of Adult Echocardiography 
 
Minimum Standard for Sickle Cell Disease 
echocardiography examinations 
 
 
1. Minimum standard study 
(RV dimension by two-dimensional measurement and the assessment of the IVC are 
included within standard study). 
 
2. Extra views 
RV views from apex 
 
3. Measurements 
Tricuspid plane systolic excursion (TAPSE) taken from nadir (not post P) to peak.  
Ensure cursor alignment is parallel to the RV free wall, perpendicular to the RV base 
scan plane. The sample volume is at the insertion point of the tricuspid leaflet.  
TAPSE of less than <1.6cm is considered abnormal. 
 
4. Doppler 
4.1 Pulsed Doppler at the level of the pulmonary valve annulus or proximal 
main pulmonary artery (wherever the signal is better) in the centre of the 
lumen.  Measure time from commencement of the signal to peak velocity.   
Time > 105 ms is normal and < 105 ms may indicate pulmonary 
hypertension.  
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4.2 Continuous wave Doppler through the pulmonary valve to record end-
diastolic PR velocity (measured at the Q wave) 
 
4.3 Continuous wave through the tricuspid valve lined up with the TR colour 
jet if possible in all views (PS long, PS short, apical and if possible subcostal). 
Peak velocity measured at the modal signal and averaged across 5 beats in 
the presence of a variable R-R interval. 
 
4.4 Doppler tissue at the lateral border of the tricuspid annulus.  Measure 
peak systolic velocity (RV S’) at the modal signal.  
<10cm/s is considered abnormal. 
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APPENDIX A3 
  
List of baseline echocardiographic parameters with 
description of  measurement technique 
 
• Right ventricular size (RV size): 
§ Modality: 2D imaging 
§ Timing: end-diastole 
§ View: apical 4-chamber view; apical window. 
§ Description: diameter at the maximal short-axis 
dimension at the basal level (basal one third of right 
ventricle). 
 
• Peak tricuspid regurgitation velocity (TR Vmax): 
§ Modality: spectral Doppler imaging continuous wave 
§ Timing: systole 
§ View: 4-chamber view (apical or subcostal window); long 
and short axis views (parasternal window).  
§ Description: measured at the modal systolic peak of the 
tricuspid regurgitation signal.  
 
• Pulmonary valve acceleration time (PV AT): 
§ Modality: spectral Doppler imaging pulsed wave 
§ Timing: systole 
§ View: parasternal right ventricular outflow view or short 
axis at the level of the aortic valve; parasternal window  
§ Description: time measured from the onset of pulmonary 
flow to the peak pulmonary flow. 
 
• Mean pulmonary pressure (using end-diastolic pulmonary 
 regurgitation where possible) (MPAP): 
§ Modality: spectral Doppler imaging continuous wave 
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§ Timing: end-diastole 
§ View: parasternal right ventricular outflow view or short 
axis at the level of the aortic valve; parasternal window  
§ Description: the end-diastolic peak of the pulmonary 
regurgitation signal should be measured at the modal 
signal. 
 
• Pulmonary valve velocity time integral (PV VTI): 
§ Modality: spectral Doppler imaging pulsed wave 
§ Timing: systole 
§ View: parasternal right ventricular outflow view or short 
axis at the level of the aortic valve; parasternal window  
§ Description: the VTI should be traced along the modal 
signal from baseline to peak to baseline. 
 
• Left atrial area (LA area): 
§ Modality: 2D imaging  
§ Timing: end-diastole 
§ View: apical 4-chamber view; apical window  
§ Description: the atria should be measured from annulus 
to annulus at the blood tissue border (appendage and 
pulmonary veins should be excluded).  
 
• Right atrial area (RA area): 
§ Modality: 2D imaging  
§ Timing: end-diastole 
§ View: apical 4-chamber view; apical window  
§ Description: the atria should be measured from annulus 
to annulus at the blood tissue border (appendage and 
pulmonary veins should be excluded).  
 
• Tricuspid annular plane systolic excursion (TAPSE): 
§ Modality: m-mode  
________________________________________________________________________________________ 
Echocardiographic measures of pulmonary hypertension and the prediction of end-points in sickle cell disease 	  
151 
§ Timing: systole 
§ View: apical 4-chamber view; apical window  
§ Description: aligned with the RV free wall with the sample 
volume at the level of the tricuspid annulus. Distance 
measured from the nadir to the systolic peak on the m-
mode.  
 
• Right ventricular tissue Doppler imaging (RV TDI): 
§ Modality: tissue Doppler imaging  
§ Timing: systole 
§ View: apical 4-chamber view; apical window  
§ Description:  aligned with the RV free wall with the 
sample volume at the level of the tricuspid annulus. 
Measured at the systolic modal signal peak.  
 
• Inferior vena cava collapsibility (IVC): 
§ Modality: 2D imaging 
§ Timing: assessed in both inspiration and expiration 
§ View: subcostal short axis focusing on the IVC; subcostal 
window 
§ Description: IVC diameter <2.1 cm that collapses >50% 
with a sniff suggests a normal RA pressure of 3 mm Hg; 
IVC diameter > 2.1 cm that collapses <50% with a sniff 
suggests a high RA pressure of 15 mm Hg. When the 
IVC diameter and collapse do not fit this paradigm, an 
intermediate value of 8 mm Hg has been used.  
 
• Left ventricular outflow tract diameter (LVOT D): 
§ Modality: 2D imaging 
§ Timing: systole 
§ View: parasternal long axis; parasternal window 
§ Description: Measured 0.5-1.0cm from the insertion point 
of the aortic valve leaflets.  
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• Left ventricular outflow tract velocity time integral (LVOT VTI): 
§ Modality: spectral Doppler imaging pulsed wave 
§ Timing: systole 
§ View: apical 4- or 5 chamber view; apical window.  
§ Description: the VTI should be traced along the modal 
signal from baseline to peak to baseline. 
 
(based on recommendations from Lang et al and Rudski et al). 
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APPENDIX A4 
Data (exert only as data totals 175 pages) 
 
ID Sex Age Dis*Type Date*of*Echo Systolic Diastolic Pulse O2*Sats
1 F 69 1 28/05/2013 147 71 79 95
+ F 1 22/10/2010 114 53 77 96
2 M 23 1 06/08/2012 126 76 85 92
3 F 19 2 10/03/2010 109 71 68 98
4 M 19 1 08/02/2013 119 70 64 98
5 M 26 1 11/01/2013 98 51 77 96
M 1 26/01/2011 117 65 87 98
6 M 24 1 14/06/2011 123 62 61 95
7 F 17 1 28/02/2013 120 65 73 96
8 F 21 1 22/08/2012 130 66 76 98
9 F 29 1 19/09/2012 106 62 81 100
10 F 33 2 10/12/2012 112 75 93 98
11 F 23 1 02/04/2012 99 58 84 98
12 M 18 1 09/08/2010 117 62 68 99
13 F 30 2 08/11/2013 112 71 80 98
14 F 42 1 04/02/2013 138 86 70 99
F 1 27/02/2012 127 81 70 98
F 1 02/06/2010 87 51 80 99
15 M 30 1 10/01/2011 116 70 66 98
16 F 47 1 17/04/2012 130 69 64 100
F 1 24/05/2010 145 84 73 100
17 F 37 1 09/08/2013 121 69 64 99
18 M 28 1 26/07/2013 125 67 69 93
19 M 24 1 03/05/2012 120 61 101 92
20 M 22 1 21/06/2013 111 51 88 94
M 1 04/09/2012 114 56 70 95
M 1 24/09/2010 101 42 85 99
21 F 27 1 22/07/2011 117 80 65 100
22 M 24 1 26/09/2012 128 65 60 100
M 1 20/01/2010 128 64 73 98
23 F 22 1 09/10/2012 121 63 100 98
24 M 44 1 31/01/2013 127 74 79 98
25 M 30 1 11/11/2013 120 64 86 95
26 F 19 2 21/06/2011 92 66 67 100
27 F 17 2 15/04/2011 114 67 84 100
28 M 24 1 08/10/2013 132 79 100 94
29 F 31 2 18/11/2010 130 95 94 100
30 F 66 2 15/12/2010 143 85 71 98
31 M 50 1 06/08/2013 148 83 73 96
M 1 03/12/2010 121 77 95 96
32 F 48 1 31/10/2013 132 70 110 98
F 1 12/01/2012 132 67 94 96
F 1 03/12/2010 142 79 85 95
F 1 16/09/2009 124 85 92 95
33 F 24 1 02/12/2013 111 66 58 999
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LVOT*D PA*AccT MPAP PAEDP PV*VTI PVR TR*vel TR*jet*VTI TR*severity
1.9 110 8 2 17.4 999 1
2.2 999 999 999 999 999.000 999 1
2.6 78 999 999 23.2 1.108 2.2 NM 1
2.2 135 999 999 17.5 999.000 999 1
2.4 138 999 5 23.6 1.050 2.1 NM 1
2.5 150 999 999 16.3 999.000 999 1
2.5 145 999 3 20 999.000 999 1
2.5 170 999 999 25.2 999.000 999 1
2.0 999 999 999 999 999.000 2.2 NM 1
1.8 146 999 999 16 999.000 999 1
1.9 118 999 999 18.8 999.000 999 1
1.9 83 999 999 11.1 999.000 999 1
2.3 999 5 13 999 999.000 999 999
2.5 999 999 10 999 999.000 999 1
1.9 135 999 999 12.8 999.000 999 1
2.0 76 15 6 13 999.000 999 1
2.1 130 16 8 16 1.785 2.6 106 2
2.1 118 999 6 15.3 999.000 999 1
2.6 110 999 999 14.7 999.000 999 1
2.3 999 999 999 999 999.000 2.2 68 1
2.2 160 999 999 23 1.203 2.4 NM 1
2.2 201 999 999 22.7 1.085 2.1 73 1
2.2 149 999 999 24.2 999.000 999 1
2.4 135 999 999 16.8 1.231 1.8 46 1
2.2 145 999 999 21.8 999.000 999 1
2.3 138 999 999 16.4 999.000 999 1
2.3 999 999 6 999 999.000 999 1
2.2 999 999 999 999 999.000 1.8 NM 1
2.0 136 999 4 19.9 1.266 2.2 NM 1
2.5 999 999 3 999 999.000 2.2 62 1
2.1 135 999 999 15.9 1.418 2 NM 1
2.3 999 9 3 999 999.000 2.2 NM 1
2.6 106 999 5 26.7 999.000 999 1
1.8 128 999 999 16.2 1.271 1.8 NM 1
1.9 999 11 3 999 999.000 999 1
2.0 118 999 6 20.1 999.000 999 1
2.0 93 999 999 15.8 999.000 999 1
2.1 128 11 4 17.3 1.547 2.4 71 3
2.3 125 999 999 15.6 999.000 999 1
2.4 999 999 999 999 999.000 999 1
2.0 999 999 999 999 999.000 3.1 NM 1
1.9 150 999 999 21.2 1.292 2.4 NM 1
2.0 125 999 999 14.3 1.838 2.4 NM 1
2.0 75 999 999 16 1.910 2.8 1
2.3 118 999 999 999 999.000 2 NM 1
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LA*area RA*area TAPSE RV*TDI*S' RV*size RV*fn LVOT*VTI LVOT*D2 SV
15.5 13.8 2.4 0.12 4.1 1 25.3 3.61 71.69641
15 15 2.6 999 3.7 1 24.1 4.84 91.56554
23.6 17.8 2 0.15 4.2 1 22.3 6.76 118.3372
20 12.5 1.8 0.14 3.5 1 16.6 4.84 63.07004
23.9 16.1 2.3 999 3.7 1 21.7 5.76 98.11872
23.7 19.8 2.7 999 3.4 1 19.4 6.25 95.18125
20.9 20.2 2.3 999 3.8 1 17.2 6.25 84.3875
27.3 16.2 2.8 999 4 1 24 6.25 117.75
20 14.6 2.7 999 3.7 1 22.8 4 71.592
14.2 11.7 2.2 0.12 3.3 1 18.4 3.24 46.79856
23.8 17.8 2.3 0.14 3.7 1 23.3 3.61 66.02871
19 15.4 2.5 999 3.6 1 22.2 3.61 62.91147
15 13 999 999 3 1 999 5.29 999
19.2 14.6 1.9 999 4.1 1 15.8 6.25 77.51875
13.8 12.3 1.6 0.12 3.1 1 17.2 3.61 48.74222
16.4 12.4 2 0.09 4.1 1 17 4 53.38
32.5 23.7 3 999 4.7 1 24.7 4.41 85.5077
22.5 20.8 2.4 0.12 4.5 1 20.6 4.41 71.31411
26.7 21.4 2.4 999 4.4 1 17.3 6.76 91.80418
24.3 19.2 999 0.12 3.4 1 25.3 5.29 105.062
29 19.3 3 999 3.3 1 26 4.84 98.7844
32.1 22.6 2.9 0.18 3.6 1 21.5 4.84 81.6871
24.6 20.6 1.8 0.13 3.8 1 21.1 4.84 80.16734
21.5 13.7 999 0.15 3.1 1 18.2 5.76 82.29312
26.4 22.8 2.4 0.2 4 1 22.7 4.84 86.24638
18.8 17.1 2.3 0.14 3.7 1 20.5 5.29 85.12933
20.7 17.1 999 999 3.7 1 17.5 5.29 72.67138
16.3 15.9 2.4 999 2.9 1 28.3 4.84 107.523
32.1 24.6 3.4 999 4.7 1 28.9 4 90.746
25.9 19.3 2.5 0.15 4.7 1 24.4 6.25 119.7125
19 14.6 3 999 3 1 20.1 4.41 69.58319
20.7 16.8 2.3 0.14 3.5 1 19.3 5.29 80.14615
25.2 20.2 2.9 999 3.7 1 999 6.76 999
12.9 13.4 1.8 0.13 3.5 1 17.5 3.24 44.5095
14.4 11.8 2.3 0.13 2.6 1 20.8 3.61 58.94408
13 12.7 2.3 0.12 3.1 1 17.5 4 54.95
12.6 10.5 2.1 999 3.2 1 18.2 4 57.148
14 12.3 2.3 999 2.6 1 21.9 4.41 75.81452
26.1 26.6 2.6 999 3.6 1 20.8 5.29 86.37512
20.9 13.4 2.7 999 999 1 18.6 5.76 84.10176
21 15.3 3 0.18 3.7 1 30.7 4 96.398
20.7 14.4 2.2 0.11 2.6 1 27.7 3.61 78.49765
23.8 21.5 2.1 999 3.5 1 19.4 4 60.916
24.8 16.1 3 999 3.5 1 23 4 72.22
999 999 2.6 0.15 3.5 1 21.5 5.29 89.28198
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CO IVC LV*fn Diast Valve Additional Bilirubin Creatine PHC*Ratio
5.66402 3 1 2 1 14 3.8 50
7.05055 3 1 3 1 13 5.7 26
10.0587 3 1 1 1 46 5.2 67
4.28876 3 1 1 1 17 7.5 12
6.2796 999 1 1 1 36 8.2 9
7.32896 3 1 1 1 36 8.5 7
7.34171 3 1 1 1 34 999 999
7.18275 3 1 1 1 47 7 16
5.22622 3 1 1 1 18 999 999
3.55669 3 1 1 1 53 999 999
5.34833 3 1 1 1 41 2.8 Too+low
5.85077 3 1 1 1 12 9.7 10
999 3 1 1 1 47 13 17
5.27128 3 1 1 1 146 10.3 11
3.89938 3 1 1 1 low+normal+LV+function17 18 5
3.7366 3 1 1 1 P+SVT+and+SLE 7 10.4 13
5.98554 3 1 1 1 15 7 12
5.70513 3 1 1 1 12 8 19
6.05908 3 1 5 1 33 999 999
6.72397 3 1 1 1 36 9.6 24
7.21126 3 1 1 1 38 4.3 49
5.22797 3 1 1 1 47 9.9 8
5.53155 999 1 1 1 40 12.9 72
8.31161 8 1 1 1 51 10.8 8
7.58968 3 1 1 1 184 21.5 25
5.95905 8 1 1 1 230 10 25
6.17707 8 1 1 1 167 14 28
6.989 999 1 1 1 13 999 999
5.44476 3 1 1 1 60 14 9
8.73901 3 1 1 1 109 14 7
6.95832 3 1 1 1 55 999 999
6.33155 3 1 1 1 33 4 Too+low
999 3 1 1 1 33 6 28
2.98214 3 1 1 1 28 5 16
4.9513 3 1 1 1 28 13 Too+low
5.495 3 1 1 1 68 14 14
5.37191 3 1 1 1 19 10 7
5.38283 3 1 1 2 13 999 999
6.30538 999 1 1 1 26 999 999
7.98967 999 1 1 1 15 8 7
10.6038 3 1 1 1 50 8 31
7.37878 3 1 1 1 60 999 999
5.17786 3 1 1 1 53 4 45
6.64424 3 1 1 1 68 7.3 66
5.17835 3 1 1 1 49 999 999
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LDH Ret Hb RHC*PCWP*(mean)RHC*PAP*(mean)CWP RHC*CO*(Fick)RHC*CO*(Thermo)Hx*of*Resp*Dis ase;*1=no,*2=yesHx*of*PE
682 159 8.6 1 1
652 220 9.4 1 1
628 398 9.0 1 1
409 81 11.3 1 1
591 241 10.2 1 1
696 443 8.5 1 1
684 326 9.3 1 1
1510 306 9.0 1 1
814 196 7.7 1 1
999 999 12.4 1 1
515 192 8.6 1 1
435 999 9.4 1 1
667 180 7.4 1 1
1035 282 8.6 1 1
503 106 10.0 1 1
690 110 9.2 1 1
975 150 6.9 1 1
2215 72 6.4 1 1
665 177 10.1 1 1
672 240 8.5 2 1
839 232 9.9 2 1
811 209 7.2 1 1
609 223 8.5 1 1
930 238 8.1 2 1
857 282 10.5 1 1
1120 262 8.9 1 1
1523 254 8.5 1 1
513 192 8.5 1 1
788 242 10.0 1 1
1545 189 7.3 1 1
999 999 10.2 1 1
696 203 10.7 2 1
949 170 8.2 1 1
454 170 10.6 1 1
451 199 10.3 1 1
697 332 9.8 1 1
612 151 10.6 1 1
555 114 11.2 1 1
866 141 13.6 1 1
506 171 14.0 1 1
586 185 7.7 1 1
691 227 6.9 1 1
701 242 7.9 1 1
664 285 7.3 1 1
744 999 9.2 1 1
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Hos*Admission*NH1*YH2N *of*Hos*Admiss*within*6*months*of*the*scanDate*of Hospital admission Rea on*for*Hos*AdmissNumb r of*Bl od*Trans*receivedSym*of*CP*NH1*YH2Medical*TherapyExchange*Program*NH1*YH2
1 0 2
1 0 2
2 2 01/06/2012 01/06/2012 9 1
2 1 01/02/2010 01/02/2010 9 1
1 0 1
2 7 01/10/2012 01/10/2012 1 2 1 1
2 1 01/09/2010 01/09/2010 1 1
2 1 01/06/2011 01/06/2011 1 2
1 0 1 1
1 0 2
2 2 01/10/2012 01/10/2012 3 2 2
1 0
1 0 1
2 1 01/06/2010 01/06/2010 3 2
1 0
2 1 01/12/2012 01/12/2012 2 1 1
1 0
2 1 01/05/2010 01/05/2010 3
1 0
1 0 1
1 0
1 0 2 1
1 0
1 0 2
2 5 01/06/2013 01/06/2013 6 2 2
2 3 28/09/2012 28/09/2012 1 2 2
2 1 29/09/2010 29/09/2010 9
1 0
1 0 1
2 10 05/01/2010 05/01/2010 6 1
2 1 01/07/2012 01/07/2012 6 2
1 0
1 0 1
1 0
2 1 02/02/2011 02/02/2011 8
1 0
1 0
1 0
1 0 1
1 0 1
1 0
1 0
2 1 29/12/2010 29/12/2010 3
1 0
1 0 2
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Confounding*causesTR*Vmax*2Hos*Admission*2End*of*study Echo*to*todayNo*hos*Admission*and*then*bring*BR*acrossFollow*up*time*for*those*withOUT*hospital*admissions
999 1 01/09/2014 453 453 453
999 1 01/09/2014 1389 1389 1389
2.2 2 01/09/2014 745 999 999
999 2 01/09/2014 1611 999 999
2.1 1 01/09/2014 563 563 563
999 2 01/09/2014 590 999 999
999 2 01/09/2014 1295 999 999
999 2 01/09/2014 1157 999 999
2.2 1 01/09/2014 541 541 541
Previous+CVA 999 1 01/09/2014 729 729 729
999 2 01/09/2014 702 999 999
999 1 01/09/2014 621 621 621
999 1 01/09/2014 869 869 869
999 2 01/09/2014 1462 999 999
999 1 01/09/2014 293 293 293
999 2 01/09/2014 567 999 999
Lupus 2.6 1 01/09/2014 904 904 904
999 2 01/09/2014 1529 999 999
Ductus+arterious999 1 01/09/2014 1311 1311 1311
Acute+coronary+syndrome2.2 1 01/09/2014 854 854 854
Chronic+lung+disease2.4 1 01/09/2014 1537 1537 1537
2.1 1 01/09/2014 382 382 382
999 1 01/09/2014 395 395 395
1.8 1 01/09/2014 838 838 838
999 2 01/09/2014 430 999 999
999 2 01/09/2014 717 999 999
999 2 01/09/2014 1417 999 999
1.8 1 01/09/2014 1119 1119 1119
1 01/09/2014 695 695 695
2 01/09/2014 1661 999 999
2 01/09/2014 682 999 999
1 01/09/2014 571 571 571
1 01/09/2014 290 290 290
1 01/09/2014 1150 1150 1150
2 01/09/2014 1216 999 999
1 01/09/2014 323 323 323
1 01/09/2014 1363 1363 1363
1 01/09/2014 1336 1336 1336
1 01/09/2014 385 385 385
1 01/09/2014 1348 1348 1348
?+Pulmonary+hypertension+at+kings.+1 01/09/2014 301 301 301
1 01/09/2014 949 949 949
2 01/09/2014 1348 999 999
1 01/09/2014 1785 1785 1785
1 01/09/2014 269 269 269
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APPENDIX A5 
Data management planning checklist  
QUT Data Management Checklist 
 
Name of Principal Investigator: 
 
Kelly Victor 
Contact Details: 
 
Email: kellyvictor@hotmail.com 
Phone: +447503539795 
 
Address:  
Guy’s and St Thomas’ Hospital 
Westminster Bridge Road 
London 
SE1 7EH 
United Kingdom 
Name of Supervisor: 
(if applicable) 
 
Chief Supervisor: Dr Fiona Harden 
Supporting Supervisor: Prof John Chambers 
Research Project or Thesis Title: 
 
Echocardiography for the prediction of clinical events in 
sickle cell disease.  
Last Updated: 
 
24 April 2014 
Location/s of this document: 
(Physical and Electronic) 
 
Electronic: Guy’s and St Thomas’ Hospital – master copy 
stored on networked internal electronic server 
Physical (back up): Cardiac Outpatient’s Department, 
Ground Floor, North Wing, St Thomas’ Hospital, London, 
SE1 7EH, UK.  
 
 
It is recommended that you read the Australian Code for the Responsible Conduct 
of Research before completing this checklist.  
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Complete each relevant section of the checklist.  The checklist includes references to relevant 
sections of the ‘Guidelines for Managing Research Data at QUT’ which may help 
you complete the Checklist. 
Review and, if necessary, update the checklist regularly in consultation with your supervisor 
and/or research partners during the course of the project. Ignore any bullet points/checkbox 
options that are not applicable. Once completed, the checklist can form the basis of a ‘Data 
Management Plan’. You may wish to expand some sections and/or attach supplementary 
material.  Store the completed checklist as part of your research documentation. 
For HDR Students 
Talk through the data-related issues on the checklist with your supervisor. Contact the IT 
Helpdesk for assistance with data storage issues. Your supervisor may need to refer 
questions to the project’s chief investigator or industry partner for clarification.  You may wish 
to arrange to talk to staff in High Performance Computing and Research Support 
(HPC) who have expertise in supporting students with data management issues.  
_____________________________________________________________
_	  
_____________________________________________________________
_	  	  
1. CONTEXT 
1.1   AIMS AND PURPOSE 
This research will investigate the use of transthoracic echocardiography (TTE) in the 
diagnosis and risk-stratification of pulmonary hypertension (PHT) in patients with Sickle 
Cell Disease (SCD). The proposal aims to: determine whether, in the absence of a 
gold-standard diagnosis of PHT, peak TR velocity is associated with a high-risk of 
events including death, sickle crisis, or pulmonary hypertension (as diagnosed on right 
heart catheterisation). The second aim is to test agreement between the four commonly 
used markers of potential PHT (peak tricuspid regurgitation velocity (TRV), pulmonary 
valve acceleration time (PV AT), tricuspid annular plane systolic excursion (TAPSE) 
and right ventricular tissue Doppler imaging (RV TDI)). The third aim is to test whether 
a redefinition of pulmonary hypertension based on a combination of echo markers is a 
better predictor of pulmonary hypertension than using peak TR velocity alone.   
1.2   FUNDING SOURCE (if applicable) 
• There is no funding requirement for this project. 
1.3   DURATION (of the project) 
• As per approval with the UHREC, data collection for this project is estimated to last 
approximately one year, commencing in January 2014 with estimated completion 
in November 2014. Project write up is estimated to be completed by June 2015. 
1.4   PARTNER INSTITUTIONS (if applicable) 
• This independent research will be performed based on a collaboration between 
Queensland University of Technology and Guy’s and St Thomas’ Foundation 
Trust. 
• All research will be conducted within the Department of Echocardiography in 
collaboration with the Department of Clinical Haematology at Guy’s and St 
Thomas’ Hospital, King’s College Health Partners, United Kingdom. 
1.5 DATA COLLECTION 
1.5.1   Nature and scale of the data that will be generated or collected: 
• A cohort of approximately 600 patients diagnosed with SCD and reviewed over the 
time period 2005-2014 will be used as study participants. This is a retrospective 
study and as such data collected will include information obtained from medical 
records based on interventions performed as part of routine clinical practice. 
Information will include patient demographic and clinical parameters, blood 
laboratory results, echocardiography results, additional clinical testing, details of 
hospital admissions and medical history. All information reviewed, recorded, 
collected and collated will be in digital electronic form. 
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1.5.2  Procedures used to collect data: 
 
• All information will be obtained from patient medical records. Medical records are 
digital and will involve accessing multiple onsite electronic hospital IT systems 
including: Echopac, Medcon, EPR, PACS, and Tomcat. Permission to perform 
such a research project has been approved by Guy’s and St Thomas’ hospital as 
part of routine clinical practice. All electronic systems are accessible from the 
Cardiac Outpatients departments both at Guys, and St Thomas’ hospitals and 
permission to access these clinical areas has been sought.  
 
1.5.3   Have the data collection procedures been previously approved by QUT or are they 
an academic standard instrument? 
Please Select  
If yes, provide details of prior approval or where instruments have been used previously 
(e.g. under a similar context). 
• This project has been granted approval by the University Human Research Ethics 
Committee (UHREC). 
• This is a retrospective study with no intervention. All information has been 
obtained as part of routine clinical practice and patient care (approved by Guy’s 
and St Thomas’ Foundation Trust).  
 
1.5.4   How will the data be recorded? 
Individually identifiable  
• Please Select 
• Patient details will initially be stored within a password protected excel 
spreadsheet with restricted access (only the principal investigator). This will be 
stored on entirely safe networked hospital IT systems and medical record systems 
where all patient details are stored.  This is the standard protocol for data 
management at Guy’s and St Thomas’ Foundation Trust. There is no non-digital 
data involved in this research project. 
Re-identifiable or potentially re-identifiable 
• Please Select 
Non-identifiable 
• Please Select 
• Data removed from the hospital premises will be non-identifiable. Patients will be 
allocated a unique ID number and all identifiable information will be removed prior 
Archival Records
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to storage.  
1.5.5   Will quality control processes be implemented? 
• Please Select 
• Data obtained from analysis will be reviewed and a sample portion will be 
reinterpreted in order to ensure consistency and accuracy in data recording. 
If yes please describe below: 
• DESCRIBE 
1.5.6   Will existing datasets be used or built upon? 
• Please Select 
• There is no plan to use or build on data sets obtained as part of this research 
project. 
If yes please describe below: 
• DESCRIBE 
 
 
 
 
 
 
 
1.6   RELATED POLICIES 
Provide details of any funding body policies or research group policies that may apply 
• There is no funding requirement for this project. 
• N/A 
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1.7   RESPONSIBILITIES 
1.7.1   Provide details of the roles and responsibilities of PI, researchers, research 
assistants and/or supervisors involved in this research 
 
The principal investigator will be in charge of research design, literature review, data 
collection and analysis, and thesis write up and publication. Chief and supporting 
supervisors will provide guidance and support throughout the process.  
 
Principal Investigator:  
Kelly Victor 
Guy’s and St Thomas’ Hospital 
Westminster Bridge Road 
London 
SE17EH 
United Kingdom 
Ph: +447503539795 
Email: kellyvictor@hotmail.com 
 
Chief Supervisor: 
Dr Fiona Harden 
School of Clinical Sciences 
Faculty of Health 
Queensland University of Technology 
GPO Box 2434 
Brisbane  Australia  4001 
Ph: +61 7 3138 3528  
Email: fiona.harden@qut.edu.au 	  
Supporting supervisor: 
Prof John Chambers 
Department of Cardiology 
Guy’s and St Thomas’ Hospital 
Westminster Bridge Road 
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London SE1 7EH 
United Kingdom 
Ph: +44 2071880973  
Email: john.chambers@gstt.nhs.uk 
 
1.7.2   How/when will adherence to this data management plan be checked or 
demonstrated? 
• Adherence to the data management plan will be demonstrated on a weekly basis. 
The procedures will be reviewed trimonthly and any necessary changes will be 
updated in this document. 
1.7.3   Who will do this? 
• Kelly Victor (Principal investigator) 
1.7.4   How and when will this data management plan be reviewed? 
• As specified above, the data management plan will be reviewed trimonthly 
 
 
2. ORGANISATION OF DATA AND FILE FORMATS 
2.1   FILE STRUCTURE 
• Data will be recorded in an Excel spread sheet. Statistical analysis (anonymised 
data only) will be stored in SPSS. Additional information (including coding 
manuals) will be stored in Word. 
 
2.2   FOLDER STRUCTURE 
• As mentioned, data will be stored on networked IT hospital systems.  
 
2.3   FILE AND FOLDER NAMING CONVENTIONS 
• Data will be located on the “S drive” under “Cardiothoracics” < “Cardiology” < “Kelly 
Victor” < “MSc” < “Data_date” (where date is the date of the last update).  
• The data file name is “Data_date”. 
• All remaining documents are kept in the “MSc” folder.  
2.4   VERSION CONTROL  
• IT systems have automatic regular updates to allow for the most up to date versions 
of programs. This should alleviate any issues regarding different program versions. 
As mentioned data files will be saved as “Data_date” to ensure the most recent 
version is updated.  
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2.5   FILE FORMATS, HARDWARE AND SOFTWARE 
Describe the main file formats that will be used: 
• The main file format will be Excel (.xls), Word (.doc) and SPSS (.sps). These are 
widely used files/programs. It is unlikely and unforeseeable that such programs 
should not last until the end of the retention period.  
Tools (hardware or software) needed to create/process/visualise the data include: 
• As above, excel will be used. Statistical analysis will involve SPSS. Additional 
information will be stored in Word. 
2.6   FILE TRANSFORMATION (if applicable) 
• N/A 
 
3.  DOCUMENTATION AND METADATA 
3.1   Documentation (to inform project team members and/or secondary users about project        
methods, data collection and data preparation) includes:  
• The principal investigator is the only person involved in data collection in excel. 
However methodologies have been documented (word document) and coding 
manuals have been devised in order to guide processes and maintain consistency. 
• The excel template marks progression and additional information within the analysis 
using coding. Any changes to calculations or raw data are documented in word in 
the coding log or coding manual.  
• Objectives and research design are documented in the “Msc” folder in the “S drive”.  
3.2   Metadata standards that will be used include: 
• Software programmes allow structured metadata (e.g. include title, author, 
organisation, subjects and keywords) which can be added via "Properties".  
• A protocol for naming the directory structure and digital files will be in place. This will 
assist in controlling different versions and data updates.  
 
 
4.  STORAGE AND SECURITY 
4.1   STORAGE 
During the active stage of the research project, the data will be stored in: 
• Network Drive – ‘S Drive’ 
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Whose responsibility is the storage of the data? 
• The principal investigator is responsible for the storage of data.  
• Guy’s and St Thomas’ IT systems are responsible for regular back ups of the “S 
drive”. These are performed automatically.  
4.2   BACK-UP 
How will you back up the data? 
• As mentioned above, this is an automated system as part of the hospital 
confidential IT systems. 
• In addition to this, updated physical copies of the data will be printed and stored at 
Guy’s and St Thomas.  
How regularly will back-ups be made? 
• Back ups are completed daily 
Whose responsibility will this be? 
• Guy’s and St Thomas’ IT systems 
 
4.3   MASTER VERSION of data will be identified in the following manner: 
• A master version will be kept in electronic and physical form. The file name is 
“data_Master” and it is stored on the hospital premises. 
 
4.4   The approximate VOLUME of data that will be generated is: 
 
 
 
Please Select 
 
Please Select 
 
4.4   How will you TRANSMIT the data, if required? 
• Identifiable data will remain on hospital premises at all times and will only be 
accessed by the principal investigator for the purpose of this project.  
• Only non identifiable data will be transferred to enable statistical analysis, inference 
and project write up. 
 
 
 
Less than 5GB
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5. DATA PROTECTION, RIGHTS AND ACCESS 
5.1   PRIVACY issues 
 
The data contains personal information 
Please Select  
• Any identifiable data will only be accessed by the principal investigator. This person 
has access to this information as part of her clinical requirements and given this is a 
service evaluation project this is necessary. That said the data is still kept under a 
limited access and restricted access file which is password protected 
• No data including patient details or identifiable information will leave the hospital 
premises either in physical or electronic form. No one will have access to collated 
patient details except the principal investigator.  
• When the information has been anonymised and no longer contains identifiable 
data, then it will be shared with chief and supporting supervisors. In addition this non 
identifiable data may be shared for statistical analysis purposes and final findings 
published.  
• This project has been granted approval under the low or negligible risk University 
Human Research Ethics Committee application (certificate number 1300000756). 
 
5.1.1   If Yes, has consent has been obtained from each identified person to disclose this 
information? 
 
• Consent has not been obtained from patients as there is no patient intervention and 
patients’ do not undergo any additional testing or intervention.  
• All data collected involves that obtained in routine clinical practice and patient care.  
• Only once anonymised will the documents be shared with additional parties 
including supervisors and those involved in statistical analysis. 
 
Please Select 
 
5.1.2   If privacy restrictions apply (i.e. no consent to disclose data has been obtained), 
describe the safeguards that will be put in place to prevent unauthorised disclosure (e.g. 
data will be anonymised, encryption, password protection etc.) 
 
• As mentioned above, all data will be anonymised and password protected with 
limited and restricted access.  
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5.2  CONFIDENTIALITY 
 
The data contains confidential information 
Please Select 
 
5.2.1   If yes, how will confidentiality be protected? 
 
 
• It is a requirement of the principal investigator’s routine clinical practice and 
patient care to ensure the protection of patient details and confidentially on the 
patient’s behalf. As mentioned, any files containing personal or identifiable 
patient details will be anonymised by the principal investigator. 
5.3   The data contains culturally sensitive information. 
 
• Please Select 
 
• N/A 
 
5.4   The data contains other information that requires special treatment  
 
• N/A 
5.5   SECURITY MANAGEMENT 
How will you manage access arrangements and data security?   
• Access arrangements and data security will be the responsibility of the principal 
investigator. Where this is not possible, Guy’s and St Thomas’ IT systems will 
assist in restricted access requirements. 
 
How will you enforce permissions, restrictions and embargoes?   
• Permissions to individual documents and access restriction to folders can be put 
in place through the individual computer programs (i.e. word and excel).  
Other security issues 
• N/A 
 
Confidentiality agreement will be signed by all members of the research team
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5.6   COPYRIGHT in the data is owned by: 
 
• Collaboration between Guy’s and St Thomas’ Foundation trust (Department of 
Echocardiography and Haematology) and Queensland University of Technology. 
 
• Intellectual property documentation still to be confirmed. 
 
6. PRESERVATION RIGHTS AND LICENSING 
6.1   After the completion of the research project/thesis, the data will be retained for: 
• The research falls under “data collections where there is an obligation to lodge 
data with a national or international repository or archive for the discipline (not 
involving clinical trials)”. This would require lodgement in an archive/repository 
(i.e. the hospital archiving system) and one copy for QUT if there were a 
significant local benefit in doing so e.g. teaching.  
• Should the project be successfully published, the data would then be retained for 
5 years after the publication of results.  
• Furthermore, it is Guy’s and St Thomas’ hospital policy that patient records (from 
which the data is collected) are stored for at least 10 years.  
 
6.2   After the research project has concluded, responsibility for the data and documentation 
will rest with: 
• The patient data (files and statistical analysis) collated for the purpose of this 
project will be the responsibility of the principal investigator.  
• Patient data obtained as part of routine clinical practice is the responsibility of 
Guy’s and St Thomas’ Foundation trust.  
 
6.3   Where will the data and documentation be deposited?: 
• Data will be deposited external to QUT. It will remain on site at Guy’s and St 
Thomas’ hospital on the “S drive” (corporate internal networked IT system).  
6.4   What level of access (to the data) will be possible? 
• Files of identifiable data collected for this project will be accessible to the 
principal investigator only. It holds restricted access and is password protected. 
Joint ownership
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If the data needs to be accessed, the principal investigator can be contacted and 
the data anonymised. 
•  Files pertaining to statistical analysis for this project will be password protected. 
 
6.5   If the data and documentation will not be deposited in a repository, where will they be 
stored?: 
• As mentioned the data will be stored on Guy’s and St Thomas’ IT electronic patient 
record systems and networked internal servers.  
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APPENDIX A6 
QUT research ethics approval certificate  
	   	   	  	  
________________________________________________________________________________________ 
Echocardiographic measures of pulmonary hypertension and the prediction of end points in sickle cell disease 
 
174 
 
   
	   	   	  	  
________________________________________________________________________________________ 
Echocardiographic measures of pulmonary hypertension and the prediction of end points in sickle cell disease 
 
175 
APPENDIX A7 
 
GSST ethics letter of support 
 
  
 
 
 
 
www.guysandstthomas.nhs.uk 
Dr Ronak Rajani MD MRCP FSCTT BM 
Research and Development Theme Lead 
Cardiovascular Services 
6th Floor, East Wing 
 St Thomas' Hospital 
Westminster Bridge Road 
London SE1 7EH 
 
Direct Line: 020 7188 1076 
Fax: 020 7188 1011 
Main Switchboard: 020 7188 7188 
 
 
 
 3rd December 2013 
 
 
To Whom It May Concern,  
 
 
Re:  Ms Kelly Victor: Echocardiography for the Prediction of Clinical Events in Sickle Cell 
Disease 
 
 
I hereby confirm that the above project has been deemed as a service evaluation initiative within 
Guy’s and St Thomas’ NHS Foundation Trust. Our processes indicate that formal ethics approval is 
not required for the above project. In addition, as a service evaluation, this project would not need to 
be registered with our Research and Development Department.  
 
If I can be of any further assistance please do not hesitate to contact me. 
 
 
Kind regards, 
 
Yours sincerely,  
 
 
Dr Ronak Rajani MD MRCP FSCCT 
Consultant Cardiologist – Heart Failure/Cardiac Imaging 
Guy’s and St Thomas’ NHS Foundation Trust. 
 
Research and Development Theme Lead 
Cardiovascular Services 
Guy’s and St Thomas’ NHS Foundation Trust  
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APPENDIX A8 
External organisation memorandum of understanding 
(MOU) 
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APPENDIX A9 
Supervisor memorandum of understanding (MOU) 
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APPENDIX A10  
Code of Conduct  
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APPENDIX A11   
Moderated poster 
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ABSTRACT 
 
BACKGROUND 
 
Sickle cell disease (SCD) is one of the most common severe monogenic disorders affecting 
an estimated 30 million persons worldwide. A serious complication of SCD is pulmonary 
hypertension (PHT) for which echo is the initial screen. 
 
SUMMARY OF WORK 
 
The aim of this research was to investigate the usefulness of transthoracic echocardiography 
(TTE) measures including tricuspid regurgitation velocity maximum (TR Vmax), pulmonary 
artery acceleration time (PA AccT), tricuspid annular plane systolic excursion (TAPSE) and 
right ventricular tissue Doppler (RV TDI S’) in the diagnosis of PHT in patients with SCD.  
This was a retrospective study including demographic data, clinical parameters and 
echocardiographic results collected between November 2007 and October 2012 in a 
specialised sickle cell clinic within a tertiary institute.  
Statistical analysis compromised Spearson’s Rho and Fisher’s Exact test. Mann U Tests 
(parametric distributions), and Kauskal-Wallis tests (nonparametric distributions) were 
performed. Multiple linear and binary logistical regressions, and CART analyses were also 
used.  
SUMMARY OF RESULTS 
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There were 1002 TTEs in 504 patients. TR Vmax was only measurable in 443 (44%) TTEs. 
There was no significant correlation between TR Vmax and PA AccT, TAPSE, or RV TDI S’ 
(Fisher’s Exact Test, p>0.05).  
 
There were 148 end points (6 deaths, 2 PHT by right heart catheterisation, 140 hospital 
admissions). TR Vmax for patients with and without end points demonstrated no significant 
variation (Mann Whitney U Test: 0.423).  
 
Binary logistical and multiple linear regressions suggested echo-derived parameters did not 
significantly correlate with end points. Boosted CART showed PA AccT was the best predictor 
with a 6-fold greater influence on end points when compared to TR Vmax, TAPSE and RV 
TDI S’. 
 
DISCUSSION AND CONCLUSIONS 
 
TR Vmax was measurable in under half of the TTEs performed. PA AccT is the single best 
predictor of end points. 
 
REFERENCES 
Nil 
 
TAKE HOME MESSAGE 
 
The value of echo-derived markers of PHT is questionable with TR Vmax often not 
measureable, and of little benefit in the prediction of end points amongst patients with SCD.  
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